REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 |
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
| Large Accelerated Filer ☐ | Accelerated Filer ☐ | Emerging growth company |
| † | The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012. |
| ☐ | U.S. GAAP |
| ☒ |
| ☐ | Other |
| PCAOB ID: |
Auditors Name: Emmerich, Córdova y Asociados S. Civil de R.L . |
Location: |
PART III
ITEM 19. EXHIBITS
| Exhibit No. |
Exhibit | |
| 101.INS | Inline XBRL Instance Document | |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document | |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | |
| 104 | Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101) | |
SIGNATURES
The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this Amendment No. 1 to the annual report on Form 20-F on its behalf.
| AUNA S.A. | ||
| May 7, 2025 | ||
| By: | /s/ Gisele Remy Ferrero | |
| Name: Gisele Remy Ferrero | ||
| Title: Chief Financial Officer and Executive Vice President | ||
Contents |
Page |
|||
| F-4 | ||||
| F-5 | ||||
| F-6 | ||||
| F-7 | ||||
| F-8 -F-121 | ||||
In thousands of soles |
Note |
2024 |
2023 |
2022 |
||||||||||||
Assets |
||||||||||||||||
Current assets |
||||||||||||||||
Cash and cash equivalents |
4 |
|||||||||||||||
Trade accounts receivable |
5 |
|||||||||||||||
Other assets |
6 |
|||||||||||||||
Inventories |
7 |
|||||||||||||||
Derivative financial instruments |
8 |
|||||||||||||||
Other investments |
9 |
— | ||||||||||||||
Total current assets |
||||||||||||||||
Non-current assets |
||||||||||||||||
Trade accounts receivable |
5 |
|||||||||||||||
Other assets |
6 |
|||||||||||||||
Investments in associates and joint venture |
10 |
|||||||||||||||
Property, furniture, and equipment |
11 |
|||||||||||||||
Intangible assets |
12 |
|||||||||||||||
Right-of-use |
13 |
|||||||||||||||
Investment properties |
||||||||||||||||
Derivative financial instruments |
8 |
|||||||||||||||
Deferred tax assets |
14 |
|||||||||||||||
Other investments |
9 |
— | ||||||||||||||
Total non-current assets |
||||||||||||||||
Total assets |
||||||||||||||||
In thousands of soles |
Note |
2024 |
2023 |
2022 |
||||||||||||
Liabilities |
||||||||||||||||
Current liabilities |
||||||||||||||||
Loans and borrowings |
15 |
|||||||||||||||
Lease liabilities |
13 |
|||||||||||||||
Trade accounts payable |
16 |
|||||||||||||||
Other accounts payable |
17 |
|||||||||||||||
Provisions |
18 |
|||||||||||||||
Derivative financial instruments |
8 |
— | ||||||||||||||
Insurance contract liabilities |
32 | |||||||||||||||
Deferred income |
||||||||||||||||
Total current liabilities |
||||||||||||||||
Non-current liabilities |
||||||||||||||||
Loans and borrowings |
15 |
|||||||||||||||
Lease liabilities |
13 |
|||||||||||||||
Trade accounts payable |
16 |
|||||||||||||||
Other accounts payable |
17 |
|||||||||||||||
Derivative financial instruments |
8 |
— | — | |||||||||||||
Deferred tax liabilities |
14 |
|||||||||||||||
Deferred income |
||||||||||||||||
Total non-current liabilities |
||||||||||||||||
Total liabilities |
||||||||||||||||
Equity |
19 |
|||||||||||||||
Share capital |
||||||||||||||||
Share premium |
— | |||||||||||||||
Reserves |
||||||||||||||||
Retained losses |
( |
) | ( |
) | ( |
) | ||||||||||
Equity attributable to the owner of the Company |
||||||||||||||||
Non-controlling interest |
||||||||||||||||
Total equity |
||||||||||||||||
Total liabilities and equity |
||||||||||||||||
In thousands of soles |
Note |
2024 |
2023 |
2022 |
||||||||||||
Revenue |
||||||||||||||||
Insurance revenue |
20 |
|||||||||||||||
Healthcare services revenue |
20 |
|||||||||||||||
Sales of medicines |
20 |
|||||||||||||||
Total revenue from contracts with customers |
||||||||||||||||
Cost of sales and services |
21 |
( |
) | ( |
) | ( |
) | |||||||||
Gross profit |
||||||||||||||||
Selling expenses |
21 |
( |
) | ( |
) | ( |
) | |||||||||
Administrative expenses |
21 |
( |
) | ( |
) | ( |
) | |||||||||
(Loss) reversal for impairment of trade receivables |
5 |
( |
) | ( |
) | |||||||||||
Other expenses |
23 |
( |
) | ( |
) | ( |
) | |||||||||
Other income |
22 |
|||||||||||||||
Operating profit |
||||||||||||||||
Finance income |
24 |
|||||||||||||||
Finance income from exchange difference |
24 |
— | — | |||||||||||||
Finance costs |
24 |
( |
) | ( |
) | ( |
) | |||||||||
Finance costs from exchange difference |
24 |
( |
) | — | ( |
) | ||||||||||
Net finance cost |
( |
) |
( |
) |
( |
) | ||||||||||
Share of profit of equity-accounted investees |
10 |
|||||||||||||||
Income (loss) before tax |
( |
) |
( |
) | ||||||||||||
Income tax expense |
27 |
( |
) | ( |
) | ( |
) | |||||||||
Profit (loss) for the year |
( |
) |
( |
) | ||||||||||||
Other comprehensive income |
||||||||||||||||
Items that are or may be reclassified subsequently to profit or loss |
||||||||||||||||
Cash flow hedges |
||||||||||||||||
Foreign operations – Foreign currency translation differences |
( |
) | ( |
) | ||||||||||||
Remeasurements of defined benefit liability |
17 |
( |
) | ( |
) | |||||||||||
Change in fair value of put liability |
— | ( |
) | |||||||||||||
Other investments at FVOCI – net change in fair value |
— | |||||||||||||||
Equity-accounted investees – share of OCI |
10 |
— | ( |
) | ( |
) | ||||||||||
Income tax |
( |
) | ( |
) | ( |
) | ||||||||||
Other comprehensive income (loss) for the year, net of tax |
( |
) |
( |
) | ||||||||||||
Total comprehensive income (loss) for the year |
( |
) |
( |
) | ||||||||||||
Income (loss) attributable to: |
||||||||||||||||
Owner of the Company |
( |
) | ( |
) | ||||||||||||
Non-controlling interest |
19.G |
|||||||||||||||
( |
) |
( |
) | |||||||||||||
Total comprehensive income (loss) attributable to: |
||||||||||||||||
Owner of the Company |
( |
) | ( |
) | ||||||||||||
Non-controlling interest |
19.G |
( |
) | ( |
) | |||||||||||
( |
) |
( |
) | |||||||||||||
Earnings per share |
||||||||||||||||
Basic earnings per share |
19 - 25 |
( |
) | ( |
) | |||||||||||
Diluted earnings per share |
19 - 25 |
( |
) | ( |
) | |||||||||||
Equity attributable to the owner of the Company |
||||||||||||||||||||||||||||||||||||||||||||||||||
In thousands of soles |
Note |
Share capital (note 19.A) |
Share premium |
Other capital reserve (note 19.B) |
Translation reserve (note 19.C) |
Cost of hedging reserve (note 19.D) |
Hedging reserve (note 19.E) |
Merger and other reserves (note 19.F) |
Shared- based payment reserve (note 33) |
Retained earnings (losses) |
Total |
Non- controlling interest (note19.G) |
Total equity |
|||||||||||||||||||||||||||||||||||||
Balances as of January 1, 2022 |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
||||||||||||||||||||||||||||||||||||||||
Loss for the year |
— | — | — | — | — | — | — | — | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||||||||||||
Other comprehensive loss for the year |
— | — | — | ( |
) | ( |
) | — | — | ( |
) | ( |
) | ( |
) | |||||||||||||||||||||||||||||||||||
Total comprehensive loss for the year |
— |
— |
— |
( |
) |
( |
) |
— |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||||||||||||||||
Contributions from non-controlling shareholder |
— | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||
Acquisition of subsidiary with NCI |
— | — | — | — | — | — | ( |
) | — | — | ( |
) | ( |
) | ||||||||||||||||||||||||||||||||||||
Transfer to legal reserve |
— | — | — | — | — | — | — | ( |
) | — | — | — | ||||||||||||||||||||||||||||||||||||||
Shareholder’s downstream merger |
— | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||
Total transactions with the owners of the Company |
— |
— |
— |
— |
— |
— |
( |
) |
||||||||||||||||||||||||||||||||||||||||||
Balances as of December 31, 2022 |
( |
) |
( |
) |
( |
) |
( |
) |
||||||||||||||||||||||||||||||||||||||||||
Balances as of January 1, 2023 |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||||||||||||||||||
Loss for the year |
— | — | — | — | — | — | — | — | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||||||||||||
Other comprehensive income for the year |
— | — | — | ( |
) | — | — | |||||||||||||||||||||||||||||||||||||||||||
Total comprehensive income for the year |
— |
— |
— |
( |
) |
— |
( |
) |
||||||||||||||||||||||||||||||||||||||||||
Transfer to legal reserve |
— | — | — | — | — | — | — | ( |
) | — | — | — | ||||||||||||||||||||||||||||||||||||||
Changes of participation NCI in subsidiary |
19.G |
— | — | — | ( |
) | — | — | ( |
) | — | |||||||||||||||||||||||||||||||||||||||
Contributions from non-controlling Shareholder |
— | — | — | — | — | — | ( |
) | — | — | ( |
) | ||||||||||||||||||||||||||||||||||||||
Shareholder’s downstream merger |
19.A |
( |
) | ( |
) | — | — | — | — | — | ( |
) | ( |
) | — | ( |
) | |||||||||||||||||||||||||||||||||
Dividend distribution |
— | — | — | — | — | — | — | — | — | ( |
) | ( |
) | |||||||||||||||||||||||||||||||||||||
Equity-settled share-based payment |
33 |
— | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||
Total transactions with the owners of the Company |
( |
) |
( |
) |
( |
) |
— |
( |
) |
( |
) |
( |
) | |||||||||||||||||||||||||||||||||||||
Balances as of December 31, 2023 |
— |
( |
) |
( |
) |
|||||||||||||||||||||||||||||||||||||||||||||
Balances as of January 1, 2024 |
— | ( |
) | ( |
) | |||||||||||||||||||||||||||||||||||||||||||||
Profit for the year |
— | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||
Other comprehensive loss the year |
— | — | — | ( |
) | ( |
) | — | — | ( |
) | ( |
) | ( |
) | |||||||||||||||||||||||||||||||||||
Total comprehensive loss for the year |
— |
— |
— |
( |
) |
( |
) |
— |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||||||||||||||||||
Issuance of common stock, net of issuance costs |
— | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||
Transfer to legal reserve |
— | — | — | — | — | — | — | ( |
) | — | — | — | ||||||||||||||||||||||||||||||||||||||
Capitalization of merger reserve |
— | — | — | — | — | ( |
) | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||
Reclassification of shared-based payment reserve |
— | — | — | — | — | — | — | ( |
) | — | — | — | ||||||||||||||||||||||||||||||||||||||
Changes of participation NCI in subsidiary |
( |
) | — | |||||||||||||||||||||||||||||||||||||||||||||||
Issuance of shares |
— | — | — | — | — | ( |
) | — | — | — | — | |||||||||||||||||||||||||||||||||||||||
Acquisition of non-controlling interest |
19.F |
— | — | — | — | — | ( |
) | — | — | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||||||||||
Derecognition of put liability |
— | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||
Dividend distribution |
— | — | — | — | — | — | — | — | — | — | ( |
) | ( |
) | ||||||||||||||||||||||||||||||||||||
Equity-settled share-based payment |
33 |
— | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||
Total transactions with the owners of the Company |
— |
— |
( |
) |
( |
) |
( |
) |
||||||||||||||||||||||||||||||||||||||||||
Balances as of December 31, 2024 |
( |
) |
( |
) |
( |
) |
||||||||||||||||||||||||||||||||||||||||||||
In thousands of soles |
Note |
2024 |
2023 |
2022 |
||||||||||
Cash flows from operating activities |
||||||||||||||
Profit (loss) for the year |
( |
) | ( |
) | ||||||||||
Adjustments for: |
||||||||||||||
Depreciation |
11 |
|||||||||||||
Depreciation of right-of-use |
13 |
|||||||||||||
Amortization |
12 |
|||||||||||||
Change in fair value of investment property |
( |
) | ( |
) | ( |
) | ||||||||
(Reversal) Impairment of inventories |
( |
) | ||||||||||||
Equity-settled share-based payment transactions |
— | |||||||||||||
Gain (loss) on disposal of property, furniture, and equipment |
11 |
( |
) | |||||||||||
Loss on disposal of right-of-use |
13 |
( |
) | |||||||||||
Loss on disposal of intangibles |
23 |
|||||||||||||
Other expenses for derecognition of other assets |
— | — | ||||||||||||
Other expenses for changes in contingent consideration |
23 |
— | — | |||||||||||
Other income for reversal of contingent consideration |
22 |
— | ( |
) | — | |||||||||
Other income for reversal of others accounts payable to former shareholders |
22 |
( |
) | — | — | |||||||||
Reversal (loss) for impairment of trade receivables |
5 |
( |
) | |||||||||||
Share of profit of equity-accounted investees |
10 |
( |
) | ( |
) | ( |
) | |||||||
Provisions |
18 |
|||||||||||||
Finance income |
24 |
( |
) | ( |
) | ( |
) | |||||||
Finance costs |
24 |
|||||||||||||
Tax expense |
27 |
|||||||||||||
Net changes in assets and liabilities |
||||||||||||||
Trade accounts receivable and other assets |
( |
) | ( |
) | ( |
) | ||||||||
Inventories |
( |
) | ( |
) | ( |
) | ||||||||
Trade accounts payable and other accounts payable |
( |
) | ||||||||||||
Provisions and employee benefits |
18 |
( |
) | ( |
) | ( |
) | |||||||
Insurance contract liabilities |
( |
) | ( |
) | ||||||||||
Cash generated from operating activities |
||||||||||||||
Income tax paid |
( |
) | ( |
) | ( |
) | ||||||||
Interest received |
||||||||||||||
Net cash from operating activities |
||||||||||||||
Cash flows from investing activities |
||||||||||||||
Acquisition of subsidiary, net of cash acquired |
1.C |
— | ( |
) | ( |
) | ||||||||
Payment for accounts payable to former shareholder |
1.C.i |
( |
) | ( |
) | — | ||||||||
Purchase of properties, furniture, and equipment |
11 |
( |
) | ( |
) | ( |
) | |||||||
Purchase of intangibles |
12 |
( |
) | ( |
) | ( |
) | |||||||
Dividends from equity-accounted investees |
10 |
|||||||||||||
Other assets (Trust funds) |
1.C.ii |
— | ( |
) | ||||||||||
Purchase of other investments, net of sales |
( |
) | ( |
) | — | |||||||||
Proceeds from sale of property, furniture, and equipment |
||||||||||||||
Payment for contingent consideration |
( |
) | ( |
) | ( |
) | ||||||||
Proceeds from (payment in advance for) purchase of shares |
— | ( |
) | |||||||||||
Net cash used in investing activities |
( |
) |
( |
) |
( |
) | ||||||||
Cash flows from financing activities |
||||||||||||||
Proceeds from issuance of common stock in initial public offering, net of issuance costs |
15 |
— | — | |||||||||||
Payments of initial public offering costs |
15 |
( |
) | — | — | |||||||||
Proceeds from loans and borrowings |
15 |
|||||||||||||
Payment for loans and borrowings |
15 |
( |
) | ( |
) | ( |
) | |||||||
Payment for lease liabilities |
15 |
( |
) | ( |
) | ( |
) | |||||||
Penalty paid for debt prepayment |
15 |
— | ( |
) | ( |
) | ||||||||
Payment for derivatives premiums |
15 |
( |
) | ( |
) | ( |
) | |||||||
Payment for costs of extinguishment of debt |
15 |
( |
) | — | — | |||||||||
Interest paid |
15 |
( |
) | ( |
) | ( |
) | |||||||
Proceeds from settlement of derivatives - interest rate swaps |
( |
) | — | — | ||||||||||
Dividends paid |
19.G |
( |
) | ( |
) | ( |
) | |||||||
Contributions from non-controlling shareholders |
15 & 19 |
— | ||||||||||||
Acquisition of non-controlling interest |
19.F |
( |
) | — | — | |||||||||
Net cash (used in) from financing activities |
( |
) |
( |
) |
||||||||||
Net increase in cash and cash equivalents |
||||||||||||||
Cash and cash equivalents at January 1 |
||||||||||||||
Cash and cash equivalents arising from shareholder’s downstream merger |
— | — | ||||||||||||
Effect of movements in exchange rates on cash held |
( |
) | ( |
) | ( |
) | ||||||||
Cash and cash equivalents at December 31 |
||||||||||||||
Transactions not representing cash flows |
||||||||||||||
Assets acquired through finance lease and other financing |
13 |
|||||||||||||
Assets acquired from suppliers in installments |
11 |
( |
) | |||||||||||
1. |
Economic Activity |
A. |
Business activity |
B. |
Approval of the consolidated financial statements |
C. |
Acquisition of subsidiaries |
i. |
Dentegra Seguros Dentales, S.A. |
In thousands of soles |
Note |
|||||
Cash and cash equivalents |
||||||
Other accounts receivables |
||||||
Other investments |
||||||
Intangible assets |
12 |
|||||
Property, furniture and equipment |
11 |
|||||
Deferred tax assets |
||||||
Trade accounts payable and other accounts payable |
( |
) | ||||
Insurance contract liabilities |
32 |
( |
) | |||
Total identifiable net assets acquired |
||||||
In thousands of soles |
||||
Cash |
||||
Account payables to former shareholder |
||||
Total consideration transferred |
||||
In thousands of soles |
||||
Consideration transferred |
||||
(Less) |
||||
Fair value of identifiable net assets |
( |
) | ||
Goodwill |
||||
In thousands of soles |
||||
Consideration transferred in cash |
||||
Cash and cash equivalents from the entity |
( |
) | ||
Net cash flows incurred |
||||
Assets acquired |
Valuation technique | |
| Trademark |
ii. |
Hospital y Clínica OCA, S.A. de C.V., DRJ Inmuebles, S.A. de C.V., Inmuebles JRD 2000, S.A. de C.V. and Tovleja HG, S.A. de C.V. |
In thousands of soles |
Note |
|||||||
Cash and cash equivalents |
||||||||
Trade accounts receivable and other accounts receivables |
||||||||
Inventory |
||||||||
Intangible assets |
12 |
|||||||
Property, furniture and equipment |
11 |
|||||||
Investment properties |
||||||||
Trade accounts payable and other accounts payable |
( |
) | ||||||
Loans and borrowings |
15 |
( |
) | |||||
Contingent liabilities |
18 |
( |
) | |||||
Deferred tax liability |
14 |
( |
) | |||||
Total identifiable net assets acquired |
||||||||
In thousands of soles |
||||
Cash |
||||
Holdback |
||||
Total consideration transferred / to be transferred |
||||
In thousands of soles |
||||
Consideration transferred |
||||
Purchase price adjustment |
( |
) | ||
(Less) |
||||
Fair value of identifiable net assets |
( |
) | ||
Goodwill |
||||
In thousands of soles |
||||
Consideration transferred in cash |
||||
Cash and cash equivalents from the entities |
( |
) | ||
Net cash flows incurred |
||||
Assets and liabilities acquired |
Valuation technique | |
| Trademarks | “Oca” and “Doctors” are trademarks of the acquired group. These brands have a local presence and offer a broad portfolio of healthcare services to their patients. Of the three main approaches of value (income, market and cost) and the methods that include these approaches, the Group considered the relief from royalty (RFR) method within the income approach as the most appropriate to assess the value of the brands. The basic principle of the RFR method is that without ownership of the intangible in question, the user of such intangible would have to make a stream of payments to the asset owner in exchange for the rights to use that asset. By acquiring the intangible, the user avoids these payments. Based on the projections of the purchase model, the projected income and cash flow of the brands was estimated for the years 2022-2027. As of 2028, a growth of 2.3% is estimated according to Management. This growth was used to calculate the terminal value of brands that have an indefinite useful life. The royalty rate used for brand valuation was 2.5%. This royalty rate was obtained from comparable companies. Brands valuation found a nominal discount rate in MXN (WACC) by estimating a cost of debt (Kd) and equity (CoK). | |
| Customer relationship | Contracts agreed with doctors in connection with the healthcare services, mainly, in which a number of services are contracted for an established population. It is considered that they meet the criteria established for the recognition of said intangible asset. The multi-period excess earnings method (“MPEEM”) within the income approach is the most appropriate to value this asset. The MPEEM determines the value of an intangible as the present value of the incremental after-tax cash flows attributable only to the subject intangible after deducting the Contributory Asset Charges (CAC). The concept behind the CAC is that an intangible ‘rents’ or ‘leases’ from a hypothetical third party all the assets it requires to produce the cash flows resulting from its development, that each project leases only those assets it needs (including trading elements) and not those it does not need, and that each project pays to the owner of the assets a fair return (where appropriate) on the value of the leased assets. | |
| Property, furniture and equipment and Investment properties |
iii. |
Oncomedica S.A. |
In thousands of soles |
Note |
|||||
Cash and cash equivalents |
||||||
Trade accounts receivable and other accounts receivables |
||||||
Inventory |
||||||
Intangible assets |
12 |
|||||
Property, furniture and equipment |
11 |
|||||
Right-of-use |
13 |
|||||
Trade accounts payable and other accounts payable |
( |
) | ||||
Loans and borrowings |
15 |
( |
) | |||
Lease liabilities |
13 |
( |
) | |||
Deferred tax liability |
14 |
( |
) | |||
Total identifiable net assets acquired |
||||||
In thousands of soles |
||||
Cash |
||||
Contingent consideration |
||||
Total consideration transferred |
||||
| • | The non-controlling shareholders with |
| • | The non-controlling shareholders with |
In thousands of soles |
||||
Consideration transferred |
||||
Non-controlling interest |
||||
(Less) |
||||
Fair value of identifiable net assets |
( |
) | ||
Goodwill |
||||
In thousands of soles |
||||
Consideration transferred |
||||
Cash and cash equivalents from Oncomedica S.A. and Subsidiaries |
( |
) | ||
Net cash flows incurred |
||||
Assets and liabilities acquired |
Valuation technique | |
| Trademarks | IMAT is the trademark of the acquired group. This brand has a local presence and offers a broad portfolio of healthcare services to patients. Of the three main approaches of value (income, market and cost) and the methods that include these approaches, the Company considered the relief from royalty (RFR) method within the income approach as the most appropriate to assess the value of the IMAT brand. The basic principle of the RFR method is that without ownership of the intangible in question, the user of such intangible would have to make a stream of payments to the asset owner in exchange for the rights to use that asset. By acquiring the intangible, the user avoids these payments. Based on the projections of the purchase model, the projected income and cash flow of IMAT was estimated for the years 2022-2027, and as of 2028, a growth of 2.93% is estimated according to Management. This growth was used to calculate the terminal value of brands that have an indefinite useful life. The royalty rate used for brand valuation is 2.70%. This royalty rate was obtained from comparable companies. Brand valuation found a nominal discount rate in COP (WACC) by estimating a cost of debt (Kd) and equity (CoK). Additionally, a premium of 1.0% will be considered on the WACC related to the lower liquidity of the intangible asset compared to other assets (considered discount rate of 14.03%). | |
| Property, furniture and equipment | ||
| Loans and borrowings | ||
D. |
Regulatory agency for private healthcare services |
2. |
Basis for the Preparation of Consolidated Financial Statements |
A. |
Basis of accounting |
B. |
Basis of measurement |
C. |
Functional and presentation currency |
D. |
Use of judgments and estimates |
i. |
Judgments |
| • | CGU: whether a group of assets that generate cash flows and that are largely independent of the cash inflows of other assets or group of assets is a CGU (note 3.F); |
| • | leases: whether an arrangement contains a lease (note 3.J); |
| • | lease term: whether the Group is reasonably certain to exercise extension options (note 3.J); and |
| • | reverse factoring: presentation of amounts related to supplier finance arrangements in the statement of financial position and in the statement of cash flow. |
ii. |
Assumptions and estimation uncertainties |
| • | Impairment test of intangible assets and goodwill: key assumptions underlying recoverable amounts (note 12); |
| • | Recognition of deferred tax asset: availability of future taxable profit against which deductible temporary differences and tax losses carried forward can be utilized (note 14); |
| • | Recognition and measurement of provisions: key assumptions about the likelihood and magnitude of an outflow of resources (note 18); |
| • | Measurement of defined benefit obligations: key actuarial assumptions (note 17); |
| • | Measurement of ECL allowance for trade receivables: key assumptions in determining the weighted-average loss rate (note 5); and |
| • | Acquisition of subsidiary: fair value of the consideration transferred and fair value of the assets acquired and liabilities (note 1.C). |
3. |
Material Accounting Policies |
A. |
Basis of consolidation |
i. |
Business combinations |
ii. |
Subsidiaries |
iii. |
Non-controlling interest |
iv. |
Common control transactions |
v. |
Associates |
vi. |
Joint arrangements |
vii. |
Transactions eliminated on consolidation |
B. |
Financial instruments |
i. |
Recognition and initial measurement |
ii. |
Classification and subsequent measurement |
| • | Financial assets |
| • | It is held within a business model whose objective is to hold assets to collect contractual cash flows; and |
| • | Its contractual terms give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. |
| • | It is held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial assets; and |
| • | Its contractual terms give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. |
| • | The stated policies and objectives for the portfolio and the operation of those policies in practice. These include whether Management’s strategy focuses on earning contractual interest income, maintaining a particular interest rate profile, matching the duration of the financial assets to the duration of any related liabilities or expected cash outflows or realizing cash flows through the sale of the assets; |
| • | How the performance of the portfolio is assessed and reported to the key personnel of the Group’s Management; |
| • | The risks that affect the performance of the business model (and the financial assets held within that business model) and how those risks are managed; |
| • | How managers of the business are compensated – e.g., whether compensation is based on the fair value of the assets managed or the contractual cash flows collected; and |
| • | The frequency, value, and timing of sales in prior periods, the reasons for such sales and expectations about future sales. |
| • | Contingent events that would change the amount or timing of cash flows; |
| • | Terms that may adjust the contractual coupon rate, including variable-rate features; |
| • | Prepayment and extension features; and |
| • | Terms that limit the Group’s claim to cash flows from specified assets (e.g., non-recourse features). |
| Financial assets at FVTPL | These assets are subsequently measured at fair value. Net gains and losses, including any interest or dividend income, are recognized in profit or loss. However, see note 3.B.v for derivatives designated as hedging instruments. | |
| Financial assets at amortized cost | These assets are subsequently measured at amortized cost using the effective interest method. The amortized cost is reduced by impairment losses. Interest income, foreign exchange gains and losses, and impairment are recognized in profit or loss. Any gain or loss on derecognition is also recognized in profit or loss. | |
| Debt investments at FVOCI | These assets are subsequently measured at fair value. Interest income calculated using the effective interest method, foreign exchange gains and losses and impairment are recognized in profit or loss. Other net gains and losses are recognized in OCI. On derecognition, gains and losses accumulated in OCI are reclassified to profit or loss. | |
| Equity investments at FVOCI | These assets are subsequently measured at fair value. Dividends are recognized as income in profit or loss unless the dividend clearly represents a recovery of part of the cost of the investment. Other net gains and losses are recognized in OCI and are never reclassified to profit or loss. |
| • | Financial liabilities |
iii. |
Derecognition |
iv. |
Offsetting |
v. |
Derivative financial instruments |
C. |
Impairment |
i. |
Non-derivative financial assets |
| • | Significant financial difficulty of the debtor or issuer; |
| • | A breach of contract such as a |
| • | It is probable that the debtor will enter bankruptcy or other financial reorganization; or |
| • | The disappearance of an active market for a security because of financial diff icultie s. |
ii. |
Non-financial assets |
D. |
Cash and cash equivalents |
E. |
Inventories |
F. |
Intangibles |
Years |
||||
Software |
||||
Customer relationships |
||||
Surface rights agreement |
||||
G. |
Property, furniture and equipment |
i. |
Recognition and measurement |
ii. |
Subsequent expenditure |
iii. |
Depreciation |
Years |
||||
Buildings and premises |
||||
Medical equipment |
||||
Vehicles |
||||
Furniture, fixtures and various equipment |
||||
IT equipment |
||||
H. |
Public service concession arrangements |
I. |
Assets held-for-sale |
J. |
Leases |
i. |
As a lease |
| • | Fixed payments, including in-substance fixed payments; |
| • | Variable lease payments that depend on an index or a rate, initially measured using the index or rate as at the commencement date; |
| • | Amounts expected to be payable under a residual value guarantee; and |
| • | The exercise price under a purchase option that the group is reasonably certain to exercise, lease payments in an optional renewal period if the Group is reasonably certain to exercise an extension option, and penalties for early termination of a lease unless the Group is reasonably certain not to terminate early. |
K. |
Trade accounts payable |
L. |
Employee benefits |
M. |
Insurance contracts |
| • | The beginning of the coverage period of the group of contracts; |
| • | The date when the first payment from a policyholder in the group is due, or when the first payment is received if there is no due date; and |
| • | For a group of onerous contracts, as soon as facts and circumstances indicate that the group is onerous. |
| • | Both of the following criteria are satisfied; |
| • | The Group has the practical ability to reassess the risks of the portfolio of insurance contracts that contain the contract and, as a result, can set a price or level of benefits that fully reflects the risk of that portfolio; and |
| • | The pricing of the premiums up to the date when the risks are reassessed does not take into account the risks that relate to periods after the reassessment date. |
| • | The rights and obligations relating to the contract are extinguished (i.e., discharged, cancelled or expired). |
| • | The contract is modified such that the modification results in a change in the measurement model or the applicable standard for measuring a component of the contract, substantially changes the contract boundary, or requires the modified contract to be included in a different group. In such cases, the Group derecognizes the initial contract and recognizes the modified contract as a new contract. |
N. |
Provisions |
O. |
Government grants |
P. |
Income tax |
| • | Temporary differences on the initial recognition of assets or liabilities in a transaction that is not a business combination and that affects neither accounting nor taxable profit or loss; |
| • | Temporary differences related to investments in subsidiaries, associates and joint arrangements to the extent that the Group is able to control the timing of the reversal of the temporary differences and it is probable that they will not reverse in the foreseeable future; and |
| • | Taxable temporary differences arising on the initial recognition of goodwill. |
Q. |
Share capital and share premium |
R. |
Dividend distribution |
S. |
Contingent liabilities and assets |
T. |
Revenue recognition |
i. |
Revenue recognition from oncologic healthcare plans |
ii. |
Revenue recognition from general healthcare services plan |
iii. |
Healthcare services |
iv. |
Sales of medicines |
Type of service |
Nature and timing of satisfaction of performance obligations, including significant payment terms |
Revenue recognition under IFRS 15 | ||
| Healthcare services | The patient acquires control of the use of the healthcare service with the provision of the service, because the patient receives and consumes the benefits granted by the Group as it provides the service. Invoices are generated at that point in time, as services are rendered, with the exception of patients who have medical insurance, which are issued according to the contractual terms agreed with the insurance companies. Uninvoiced amounts are presented as revenue and trade receivables. Advances are primarily received from patients who do not have medical insurance for healthcare services such as hospitalization. These advances are recognized in revenue as services are rendered over time. |
Revenue is recognized when services are rendered. Revenue is recognized over time based on the cost of the services, products and supplies utilized in providing such treatment. The variable consideration is determined using the expected value with statistics of historical percentages for the last year and is updated at the end of each month. Advances received were included in trade payable. Healthcare services revenue is recognized on the date the patient receives treatment and includes amounts related to certain services, products and supplies utilized in providing such treatment. The selling price is determined based upon the company’s standard rates or at rates determined under reimbursement arrangements. These arrangements are generally with third parties such as commercial insurers. Revenue from contracts with third-party payers is recognized to the extent that it is highly probable that a significant reversal in the amount of accrued revenue will not occur. Therefore, the amount of the recognized income is adjusted by the expected claims that are estimated based on the historical data of the issued credit notes. Some contracts permit the insurers to get discounts for prompt pay. Management works with statistics which are estimated based on historical percentages and these are recognized as a lower value of revenue. | ||
| Sale of medicines | Customers acquire control of the medicines, when they are delivered and have been accepted, either as part of the hospitalization or as part of the pharmacy sale. Invoices are generated at the time the customers receive the medicines and in the case of hospitalization at the time of the medicine is delivered. |
Revenue is recognized when medicines are delivered and have been accepted by customers at their premises. Revenue from the sale of medicines delivered during hospitalization is recognized at the estimated net realization amount at the time the medicine is received by the patient. | ||
U. |
Cost and expense recognition |
V. |
Finance income and finance costs |
| • | Interest income; |
| • | Interest expense; |
| • | The net gain or loss on financial assets at FVTPL; |
| • | The net gain or loss on the disposal of investments in debt securities measured at FVOCI; |
| • | The foreign currency gain or loss on financial assets and financial liabilities; and |
| • | The reclassification of net gains and losses previously recognized in OCI on cash flow hedges of interest rate risk and foreign currency risk for borrowings. |
W. |
Foreign currency transactions and balances |
X. |
Written Put and Call Options in Business combinations |
| • | The anticipated-acquisition method: The contract is accounted for as an anticipated acquisition of the underlying non-controlling interest as if the put option had been exercised already or the forward had been satisfied by the non-controlling shareholders. This is independent of how the exercise price is determined and how likely it is that the option will be exercised. |
| • | The present-access method: Under this method, non-controlling interest continues to be recognized because the non-controlling shareholders still have present access to the returns associated with the underlying ownership interests; therefore, the debit entry is to “other” equity. |
| • | From an economic perspective, the instrument will be exercised in substantially all cases. |
| • | The sensitivity of the exercise price to the variations in the fair value of the ownership interest is sufficiently low that substantially all of that variation accrues to the parent. |
Y. |
Share-based payments |
Z. |
IFRS’ new amendments of mandatory application as of the periods beginning on January 1, 2024 |
Effective date |
New standards or amendments | |
| January 1, 2024 | • Non-current Liabilities with Covenants – Amendments IAS 1 and Classification of Liabilities as Current or Non-current – Amendments to IAS 1 | |
• Lease Liability in a Sale and Leaseback – Amendments to IFRS 16 | ||
• Supplier Finance Arrangements – Amendments to IAS 7 and IFRS 7 |
AA. |
Standards issued but not yet effective |
Effective date |
New standards or amendments | |
| January 1, 2025 | • Lack of Exchangeability – Amendments to IAS 21 | |
| January 1, 2026 | • Classification and Measurement of Financial Instruments – Amendments to IFRS 9 and IFRS 7 • Annual Improvements to IFRS Accounting Standards – Volume 11 | |
| January 1, 2027 | • IFRS 18 - Presentation and Disclosure in Financial Statements • IFRS 19 - Subsidiaries without Public Accountability: Disclosures | |
| Available for optional adoption/ effective date deferred indefinitely |
• Sale or Contribution of Assets between an Investor and its Associate or Joint Venture – Amendments to IFRS 10 and IAS 28. | |
| • | Entities are required to classify all income and expenses into five categories in the statement of profit or loss, namely the operating, investing, financing, discontinued operations and income tax categories. Entities are also required to present a newly-defined operating profit subtotal. Entities’ net profit will not change. |
| • | Management-defined performance measures (MPMs) are disclosed in a single note in the financial statements. |
| • | Enhanced guidance is provided on how to group information in the financial statements. |
| • | Lack of Exchangeability (Amendments to IAS 21). |
| • | Classification and Measurement of Financial Instruments (Amendments to IFRS 9 and IFRS 7). |
BB. |
Sustainability policy pronouncements not yet effective |
New IFRS of Sustainability |
Effective date | |
| IFRS S1 General Requirements for Disclosures about Sustainability Disclosures Related to Financial Information | Annual periods beginning on or after January 1, 2024. Early adoption is permitted with the joint application of IFRS S2. | |
| IFRS S2 Climate-related Disclosures | Annual periods beginning on or after January 1, 2024. Early adoption is permitted with the joint application of IFRS S1. | |
4. |
Cash and Cash Equivalents |
In thousands of soles |
2024 |
2023 |
2022 |
|||||||||
Checking accounts (a) |
||||||||||||
Term deposits (b) |
||||||||||||
Cash funds |
||||||||||||
| (a) | As of December 31, 2024, checking accounts are held at local and foreign banks in local and foreign currency amounting to S/ |
| (b) | As of December 31, 2024, it includes overnight term deposits held at local and foreign banks in local and foreign currency amounting for S/ |
| • | In accordance with the information provided by Apoyo y Asociados Internacionales S.A.C., an international rating agency (applicable to Peruvian financial entities): |
In thousands of soles |
2024 |
2023 |
2022 |
|||||||||
Bank deposits and accounts |
||||||||||||
A+ |
||||||||||||
AA+ |
||||||||||||
A- |
||||||||||||
A |
||||||||||||
| • | In accordance with the information provided by an international rating agency (applicable to Colombian financial entities): |
In thousands of soles |
2024 |
2023 |
2022 |
|||||||||
Bank deposits and accounts |
||||||||||||
AAA |
||||||||||||
AA+ |
||||||||||||
AA- |
||||||||||||
| • | In accordance with the information provided by an international rating agency (applicable to Mexican financial entities): |
In thousands of soles |
2024 |
2023 |
2022 |
|||||||||
Bank deposits and accounts |
||||||||||||
AAA |
||||||||||||
A |
||||||||||||
AA |
||||||||||||
BBB |
||||||||||||
BBB+ |
||||||||||||
BBB- |
||||||||||||
| • | In accordance with the information provided by an international rating agency (applicable to Luxembourg |
In thousands of soles |
2024 |
2023 |
2022 |
|||||||||
Bank deposits and accounts |
||||||||||||
A+ |
||||||||||||
AA |
||||||||||||
AAA |
||||||||||||
5. |
Trade Accounts Receivable |
In thousands of soles |
Note |
2024 |
2023 |
2022 |
||||||||||||
Trade accounts receivable |
||||||||||||||||
Trade accounts receivable from related parties |
31 |
|||||||||||||||
Less: Loss for impairment of trade receivables |
( |
) | ( |
) | ( |
) | ||||||||||
Current |
||||||||||||||||
Non-current |
||||||||||||||||
In thousands of soles |
2024 |
2023 |
2022 |
|||||||||
Healthcare services |
||||||||||||
In thousands of soles |
Peru |
Colombia |
México |
Total |
||||||||||||
Healthcare services |
||||||||||||||||
In thousands of soles |
Peru |
Colombia |
México |
Total |
||||||||||||
Healthcare services |
||||||||||||||||
In thousands of soles |
Peru |
Colombia |
México |
Total |
||||||||||||
Healthcare services |
||||||||||||||||
In thousands of soles |
Peru |
Colombia |
México |
Total |
||||||||||||
Current (not past due) |
||||||||||||||||
1 - 90 days past due |
||||||||||||||||
91 - 180 days past due |
||||||||||||||||
181 - 360 days past due |
||||||||||||||||
More than 360 days past due |
||||||||||||||||
In thousands of soles |
Peru |
Colombia |
México |
Total |
||||||||||||
Current (not past due) |
||||||||||||||||
1 - 90 days past due |
||||||||||||||||
91 - 180 days past due |
||||||||||||||||
181 - 360 days past due |
||||||||||||||||
More than 360 days past due |
||||||||||||||||
In thousands of soles |
Peru |
Colombia |
México |
Total |
||||||||||||
Current (not past due) |
||||||||||||||||
1 - 90 days past due |
||||||||||||||||
91 - 180 days past due |
||||||||||||||||
181 - 360 days past due |
||||||||||||||||
More than 360 days past due |
||||||||||||||||
In thousands of soles |
Weighted- average loss rate |
Gross carrying amount |
Loss allowance |
|||||||||
Current (not past due) |
% | |||||||||||
1 - 90 days past due |
% | |||||||||||
91 - 180 days past due |
% | |||||||||||
181 - 360 days past due |
% | |||||||||||
More than 360 days past due |
% | |||||||||||
In thousands of soles |
Weighted- average loss rate |
Gross carrying amount |
Loss allowance |
|||||||||
Current (not past due) |
% | |||||||||||
1 - 90 days past due |
% | |||||||||||
91 - 180 days past due |
% | |||||||||||
181 - 360 days past due |
% | |||||||||||
More than 360 days past due |
% | |||||||||||
In thousands of soles |
Weighted- average loss rate |
Gross carrying amount |
Loss allowance |
|||||||||
Current (not past due) |
% | |||||||||||
1 - 90 days past due |
% | |||||||||||
91 - 180 days past due |
% | |||||||||||
181 - 360 days past due |
% | |||||||||||
More than 360 days past due |
% | |||||||||||
In thousands of soles |
Weighted- average loss rate |
Gross carrying amount |
Loss allowance |
|||||||||
Current (not past due) |
% | |||||||||||
1 - 90 days past due |
% | |||||||||||
91 - 180 days past due |
% | |||||||||||
181 - 360 days past due |
% | |||||||||||
More than 360 days past due |
% | |||||||||||
In thousands of soles |
Weighted- average loss rate |
Gross carrying amount |
Loss allowance |
|||||||||
Current (not past due) |
% | |||||||||||
1 - 90 days past due |
% | |||||||||||
91 - 180 days past due |
% | |||||||||||
181 - 360 days past due |
% | |||||||||||
More than 360 days past due |
% | |||||||||||
In thousands of soles |
Weighted- average loss rate |
Gross carrying amount |
Loss allowance |
|||||||||
Current (not past due) |
% | |||||||||||
1 - 90 days past due |
% | |||||||||||
91 - 180 days past due |
% | |||||||||||
181 - 360 days past due |
% | |||||||||||
More than 360 days past due |
% | |||||||||||
In thousands of soles |
2024 |
2023 |
2022 |
|||||||||
Initial balance |
||||||||||||
Additions |
||||||||||||
Recovery |
( |
) | ( |
) | ( |
) | ||||||
Write-off |
( |
) | ( |
) | ( |
) | ||||||
Exchange difference |
( |
) | ( |
) | ||||||||
Final balance |
||||||||||||
6. |
Other Assets |
In thousands of soles |
2024 |
2023 |
2022 |
|||||||||
Tax credit from sales tax (VAT) (a) |
||||||||||||
Costs of anticipated equity transactions |
— | |||||||||||
Advance payment for purchase of shares (b) |
— | — | ||||||||||
Trust fund (c) |
— | — | ||||||||||
Prepaid expenses (d) |
||||||||||||
Payments in advance of income tax (e) |
||||||||||||
Accounts receivables from credit cards |
||||||||||||
Claims to third parties (f) |
||||||||||||
Account receivable from former shareholders (g) |
||||||||||||
Guarantees furnished (h) |
||||||||||||
Taxes receivable |
||||||||||||
Loans to personnel |
||||||||||||
Prepayments |
||||||||||||
Others (i) |
||||||||||||
Current |
||||||||||||
Non-current |
||||||||||||
| (a) | As of December 31, 2024, 2023 and 2022, it includes the tax credit (net) of value added tax (VAT). |
| (b) | As of December 31, 2022, it includes the payment as an advance for the acquisition of shares of the OCA Hospital through Auna Mexico, which was agreed with the former shareholder as a deposit representing the amount of S/ |
| (c) | It corresponds to the deposit of S/ |
| (d) | It corresponds to insurance paid in advance, annual licenses of software and the incremental cost of obtaining a contract with a supplier for selling oncological healthcare plans. |
| (e) | It corresponds to payments in advance of income tax, which will be offset with future income tax in the next fiscal year. |
| (f) | It includes a receivable for salaries of employees on leave that is to be refunded by the government for S/ |
| (g) | As of December 31, 2024, 2023 and 2022, it corresponds to account receivables from former shareholders for tax and labor liabilities contingencies that were determined in the acquisition of Patología Oncológica for S/ |
| (h) | It corresponds to funds under restriction in financial institutions mainly for the compliance with debts and guarantees for real estate rentals. |
| (i) | It includes accounts receivable from Consorcio Trecca for S/ |
7. |
Inventories |
In thousands of soles |
2024 |
2023 |
2022 |
|||||||||
Medicines |
||||||||||||
Medical supplies |
||||||||||||
Supplies and packaging |
||||||||||||
8. |
Derivative Financial Instruments |
A. |
Derivatives Foreign exchange operation agreements with deferred premium |
In thousands of soles |
Reference value |
Maturity date |
2024 |
2023 |
2022 |
|||||||||||||||||||
Derivative assets mandatorily measured at FVTPL |
||||||||||||||||||||||||
Fx operation Agreement – Purchased Collar |
US$ |
— | — | |||||||||||||||||||||
Fx operation Agreement – Purchased Collar |
(e | ) | US$ |
— | — | |||||||||||||||||||
Derivative assets mandatorily measured at FVOCI |
||||||||||||||||||||||||
Fx operation Agreements – Long forward |
(a | ) | US$ |
— | — | |||||||||||||||||||
Fx operation Agreements – Purchased Collar (Long Put) |
(a | ) | US$ |
— | — | ( |
) | |||||||||||||||||
Fx operation Agreements – Purchased Collar (Short Call) |
US$ |
— | — | |||||||||||||||||||||
Fx operation Agreement – Call Spread |
(a | ) | US$ |
— | — | |||||||||||||||||||
Fx operation Agreement – Call Spread (Long Put) |
(a | ) | US$ |
( |
) | — | — | |||||||||||||||||
Fx operation Agreement – Call Spread (Short Call) |
(a | ) | US$ |
— | — | |||||||||||||||||||
Fx operation Agreements – Purchased Collar (Long Put) |
(a | ) | US$ |
— | ( |
) | — | |||||||||||||||||
Fx operation Agreements – Purchased Collar (Short Call) |
(a | ) | US$ |
— | — | |||||||||||||||||||
Fx operation Agreement – Call Spread |
(b | ) | US$ |
— | ||||||||||||||||||||
Fx operation Agreement – Call Spread |
(d | ) | US$ |
— | ||||||||||||||||||||
Fx operation Agreement – Call Spread |
(d | ) | US$ |
— | ||||||||||||||||||||
Fx operation Agreement – Purchased Collar |
(c | ) | US$ |
— | — | |||||||||||||||||||
Fx operation Agreement – Single Call |
(c | ) | US$ |
— | — | |||||||||||||||||||
Interest Rate Swap – TIIE |
(f | ) | MXN |
— | — | |||||||||||||||||||
Current |
||||||||||||||||||||||||
Non-current |
||||||||||||||||||||||||
Derivative liabilities mandatorily measured at FVOCI |
||||||||||||||||||||||||
Interest Rate Swap – TIIE |
(f | ) | MXN |
— | — | |||||||||||||||||||
Interest Rate Swap – SOFR |
(f | ) | US$ |
— | — | |||||||||||||||||||
Fx operation Agreements – Purchased Collar (Long Put) |
US$ |
— | — | ( |
) | |||||||||||||||||||
Fx operation Agreements – Purchased Collar (Short Call) |
US$ |
— | — | |||||||||||||||||||||
— |
||||||||||||||||||||||||
Current |
— |
|||||||||||||||||||||||
Non-current |
— |
— |
||||||||||||||||||||||
| (a) | On November 29, 2022, the Group negotiated a new agreement with Citibank N.A. on the previous derivate structure (purchased collar and long forward for S/ 1 . As a result of this negotiation, the Group recorded an increase of the derivative financial asset with the premiums payable by S/ |
| (b) | On November 29, 2022, the Group signed a new foreign exchange options which included Call spread agreement with Citibank N.A. for S/ 1 . |
| (c) | On May 5, 2023, the Group, through its subsidiary Grupo Salud Auna Mexico, signed foreign exchange options which included a Single call agreement with Santander Bank for US$ 1 . |
| (d) | On June 1, 2023, the Group signed foreign exchange options which included a Call spread agreement with Citibank for US$ 1 . |
| (e) | On July 21, 2023, the Group, through its subsidiary Auna Colombia S.A.S., signed foreign exchange options which included a Single Call agreement with Citibank N.A. for US$ 1 . As of September 30, 2024 this derivative has finished. |
| (f) | In April 2024, the Group signed new interest rate swap agreements to cover the interest rate fluctuation related to the new term loan signed December 18, 2023. The amount covered was MXN |
9. |
Other Investments |
In thousands of soles |
2024 |
2023 |
||||||
Current investments |
||||||||
Sovereign debt securities - at FVOCI |
||||||||
Non-current investments |
||||||||
Sovereign debt securities - at FVOCI |
||||||||
10. |
Investments in Associates and Joint Venture |
In thousands of soles |
Percentage ownership interest |
2024 |
2023 |
2022 |
||||||||||||
Associates |
||||||||||||||||
Ciclotrón Colombia S.A.S. (a) |
||||||||||||||||
Ciclotrón Perú S.A. (c) |
||||||||||||||||
Joint Venture |
||||||||||||||||
Pet CT Perú S.A. (b) |
||||||||||||||||
| (a) | It is dedicated to the production and commercialization of radiopharmaceuticals used for diagnostic images of PET (positron emission tomography) and scintigraphy and its fiscal address is Calle 30 N 46 - 25 Medellín – Colombia. |
| (b) | It is dedicated to providing medical diagnostic imaging services and cancer treatment, using PET / CT molecular imaging technology. |
| (c) | It is dedicated to the production of radiopharmaceuticals used for diagnostic images of PET (positron emission tomography). |
In thousands of soles |
2024 |
2023 |
2022 |
|||||||||
Profit |
||||||||||||
Associate |
||||||||||||
Ciclotrón Colombia S.A.S. |
||||||||||||
Ciclotrón Perú S.A. |
||||||||||||
Joint Venture |
||||||||||||
Pet CT Perú S.A. |
||||||||||||
Other comprehensive income |
||||||||||||
Associate |
||||||||||||
Ciclotrón Colombia S.A.S. |
— | ( |
) | ( |
) | |||||||
In thousands of soles |
Assets |
Liabilities |
Income |
Expenses |
Interest (%) |
|||||||||||||||
As of December 31, 2024 |
||||||||||||||||||||
Ciclotrón Perú S.A. |
||||||||||||||||||||
Pet CT Perú S.A. |
||||||||||||||||||||
Ciclotrón Colombia S.A.S. |
||||||||||||||||||||
As of December 31, 2023 |
||||||||||||||||||||
Ciclotrón Perú S.A. |
||||||||||||||||||||
Pet CT Perú S.A. |
||||||||||||||||||||
Ciclotrón Colombia S.A.S. |
||||||||||||||||||||
As of December 31, 2022 |
||||||||||||||||||||
Ciclotrón Perú S.A. |
||||||||||||||||||||
Pet CT Perú S.A. |
||||||||||||||||||||
Ciclotrón Colombia S.A.S. |
||||||||||||||||||||
In thousands of soles |
2024 |
2023 |
2022 |
|||||||||
As of January 1 |
||||||||||||
Group’s share in profit or loss |
||||||||||||
Group’s share in other comprehensive income |
( |
) | ( |
) | ||||||||
Collection of dividends |
( |
) | ( |
) | ( |
) | ||||||
Exchange difference |
( |
) | ( |
) | ||||||||
As of December 31 |
||||||||||||
11. |
Property, Furniture and Equipment |
In thousands of soles |
Note |
Land (a) |
Buildings and facilities (a) |
Medical equipment and others (a) |
Vehicles |
Furniture and fixture |
Works in progress (b) |
Total |
||||||||||||||||||||||||
Cost |
||||||||||||||||||||||||||||||||
Balances as of January 1, 2022 |
||||||||||||||||||||||||||||||||
Additions |
||||||||||||||||||||||||||||||||
Business combination balances |
1.C.iii & iv |
|||||||||||||||||||||||||||||||
Reclassifications to intangible assets |
— | — | — | — | — | ( |
) | ( |
) | |||||||||||||||||||||||
Reclassifications from right-of-use |
— | — | — | — | — | |||||||||||||||||||||||||||
Transfers |
— | — | ( |
) | — | |||||||||||||||||||||||||||
Write-off (e) |
— | ( |
) | ( |
) | — | ( |
) | — | ( |
) | |||||||||||||||||||||
Disposals |
— | — | ( |
) | ( |
) | ( |
) | — | ( |
) | |||||||||||||||||||||
Exchange difference |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||
Balances as of December 31, 2022 |
||||||||||||||||||||||||||||||||
Balances as of January 1, 2023 |
||||||||||||||||||||||||||||||||
Additions (a) |
— | |||||||||||||||||||||||||||||||
Business combination balances |
1.C.i & ii |
— | — | — | ||||||||||||||||||||||||||||
Reclassifications to intangible assets |
— | — | — | — | ( |
) | ( |
) | ||||||||||||||||||||||||
Reclassifications from right-of-use |
— | — | — | — | ||||||||||||||||||||||||||||
Transfers |
— | ( |
) | ( |
) | ( |
) | — | ||||||||||||||||||||||||
Write-off (e) |
— | ( |
) | ( |
) | ( |
) | ( |
) | — | ( |
) | ||||||||||||||||||||
Disposals |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | — | ( |
) | |||||||||||||||||||
Exchange difference |
||||||||||||||||||||||||||||||||
Balances as of December 31, 2023 |
||||||||||||||||||||||||||||||||
Balances as of January 1, 2024 |
||||||||||||||||||||||||||||||||
Additions (a) |
— | |||||||||||||||||||||||||||||||
Reclassifications from intangible assets |
— | — | — | — | — | |||||||||||||||||||||||||||
Reclassifications from right-of-use |
— | — | — | — | — | |||||||||||||||||||||||||||
Transfers |
— | — | ( |
) | — | |||||||||||||||||||||||||||
Write-off (e) |
— | ( |
) | ( |
) | — | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||
Disposals |
— | — | ( |
) | ( |
) | ( |
) | — | ( |
) | |||||||||||||||||||||
Exchange difference |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||
Balances as of December 31, 2024 |
||||||||||||||||||||||||||||||||
In thousands of soles |
Note |
Land (a) |
Buildings and facilities (a) |
Medical equipment and others (a) |
Vehicles |
Furniture and fixture |
Works in progress (b) |
Total |
||||||||||||||||||||||||
Accumulated depreciation |
||||||||||||||||||||||||||||||||
Balances as of January 1, 2022 |
— | ( |
) | ( |
) | ( |
) | ( |
) | — | ( |
) | ||||||||||||||||||||
Additions (d) |
— | ( |
) | ( |
) | ( |
) | ( |
) | — | ( |
) | ||||||||||||||||||||
Reclassifications from right-of-use |
— | — | ( |
) | — | — | — | ( |
) | |||||||||||||||||||||||
Write-off (e) |
— | — | — | |||||||||||||||||||||||||||||
Disposals |
— | — | — | |||||||||||||||||||||||||||||
Exchange difference |
— | ( |
) | — | ||||||||||||||||||||||||||||
Balances as of December 31, 2022 |
— |
( |
) |
( |
) |
( |
) |
( |
) |
— |
( |
) | ||||||||||||||||||||
Balances as of January 1, 2023 |
— | ( |
) | ( |
) | ( |
) | ( |
) | — | ( |
) | ||||||||||||||||||||
Additions (d) |
— | ( |
) | ( |
) | ( |
) | ( |
) | — | ( |
) | ||||||||||||||||||||
Reclassifications from right-of-use |
— | — | ( |
) | ( |
) | — | — | ( |
) | ||||||||||||||||||||||
Write-off (e) |
— | — | ||||||||||||||||||||||||||||||
Disposals |
— | — | — | |||||||||||||||||||||||||||||
Exchange difference |
— | ( |
) | ( |
) | ( |
) | — | ( |
) | ||||||||||||||||||||||
Balances as of December 31, 2023 |
— |
( |
) |
( |
) |
( |
) |
( |
) |
— |
( |
) | ||||||||||||||||||||
Balances as of January 1, 2024 |
— | ( |
) | ( |
) | ( |
) | ( |
) | — | ( |
) | ||||||||||||||||||||
Additions (d) |
— | ( |
) | ( |
) | ( |
) | ( |
) | — | ( |
) | ||||||||||||||||||||
Reclassifications from right-of-use |
— | — | ( |
) | — | — | — | ( |
) | |||||||||||||||||||||||
Write-off (e) |
— | — | — | |||||||||||||||||||||||||||||
Disposals |
— | — | — | — | ||||||||||||||||||||||||||||
Exchange difference |
— | ( |
) | — | ||||||||||||||||||||||||||||
Balances as of December 31, 2024 |
— |
( |
) |
( |
) |
( |
) |
( |
) |
— |
( |
) | ||||||||||||||||||||
Net carrying amount |
||||||||||||||||||||||||||||||||
Balances as of December 31, 2022 |
||||||||||||||||||||||||||||||||
Balances as of December 31, 2023 |
||||||||||||||||||||||||||||||||
Balances as of December 31, 2024 |
||||||||||||||||||||||||||||||||
| (a) | In 2024, the Group acquired medical equipment for S/ |
| (b) | As of December 31, 2024, 2023 and 2022, the additions of constructions in progress amounted to S/ |
| (c) | Corresponds to transfers from right-of-use |
| (d) | The depreciation recognized in the consolidated statement of profit or loss and other comprehensive income includes: |
In thousands of soles |
Note |
2024 |
2023 |
2022 |
||||||||||||
Cost of sales and services |
21 |
|||||||||||||||
Administrative expenses |
21 |
|||||||||||||||
| (e) | The write-off corresponds mainly to the physical inventory of fixed assets of the Group in 2024 with a cost of S/ |
12. |
Intangibles Assets |
In thousands of soles |
Note |
Goodwill |
Trademark |
Customer relationships |
Software |
Public service concessions |
Total |
|||||||||||||||||||||
Cost |
||||||||||||||||||||||||||||
Balances as of January 1, 2022 |
||||||||||||||||||||||||||||
Additions |
— | — | — | |||||||||||||||||||||||||
Business combination balances |
1C.ii & iii |
— | ||||||||||||||||||||||||||
Reclassifications from property, furniture and equipment |
— | — | — | — | ||||||||||||||||||||||||
Disposal |
— | — | — | ( |
) | — | ( |
) | ||||||||||||||||||||
Exchange difference |
( |
) | ( |
) | ( |
) | ( |
) | — | ( |
) | |||||||||||||||||
Balances as of December 31, 2022 |
||||||||||||||||||||||||||||
Balances as of January 1, 2023 |
||||||||||||||||||||||||||||
Additions |
— | — | — | |||||||||||||||||||||||||
Business combination balances |
1.C.i |
— | — | — | ||||||||||||||||||||||||
Hospital y Clínica OCA’s purchase price adjustment |
1.C.ii |
( |
) | — | — | — | — | ( |
) | |||||||||||||||||||
Reclassifications from property, furniture and equipment |
— | — | — | — | ||||||||||||||||||||||||
Disposal |
— | — | — | ( |
) | — | ( |
) | ||||||||||||||||||||
Exchange difference |
— | |||||||||||||||||||||||||||
Balances as of December 31, 2023 |
||||||||||||||||||||||||||||
Balances as of January 1, 2024 |
||||||||||||||||||||||||||||
Additions |
— | — | — | |||||||||||||||||||||||||
Reclassifications from property, furniture and equipment |
— | — | — | ( |
) | — | ( |
) | ||||||||||||||||||||
Disposal |
— | — | — | ( |
) | — | ( |
) | ||||||||||||||||||||
Exchange difference |
( |
) | ( |
) | ( |
) | ( |
) | — | ( |
) | |||||||||||||||||
Balances as of December 31, 2024 |
||||||||||||||||||||||||||||
In thousands of soles |
Note |
Goodwill |
Trademark |
Customer relationships |
Software |
Public service concessions |
Total |
|||||||||||||||||||||
Accumulated amortization |
||||||||||||||||||||||||||||
Balances as of January 1, 2022 |
— | — | ( |
) | ( |
) | — | ( |
) | |||||||||||||||||||
Annual amortization |
— | — | ( |
) | ( |
) | — | ( |
) | |||||||||||||||||||
Exchange difference |
— | — | — | |||||||||||||||||||||||||
Balances as of December 31, 2022 |
— |
— |
( |
) |
( |
) |
— |
( |
) | |||||||||||||||||||
Balances as of January 1, 2023 |
— | — | ( |
) | ( |
) | — | ( |
) | |||||||||||||||||||
Annual amortization |
— | — | ( |
) | ( |
) | — | ( |
) | |||||||||||||||||||
Disposal |
— | — | — | — | ||||||||||||||||||||||||
Exchange difference |
— | — | ( |
) | ( |
) | — | ( |
) | |||||||||||||||||||
Balances as of December 31, 2023 |
— |
— |
( |
) |
( |
) |
— |
( |
) | |||||||||||||||||||
Balances as of January 1, 2024 |
— | — | ( |
) | ( |
) | — | ( |
) | |||||||||||||||||||
Annual amortization |
— | — | ( |
) | ( |
) | — | ( |
) | |||||||||||||||||||
Disposal |
— | — | — | — | ||||||||||||||||||||||||
Exchange difference |
— | — | — | |||||||||||||||||||||||||
Balances as of December 31, 2024 |
— |
— |
( |
) |
( |
) |
— |
( |
) | |||||||||||||||||||
Carrying amount |
||||||||||||||||||||||||||||
Balances as of December 31, 2022 |
||||||||||||||||||||||||||||
Balances as of December 31, 2023 |
||||||||||||||||||||||||||||
Balances as of December 31, 2024 |
||||||||||||||||||||||||||||
In thousands of soles |
Note |
2024 |
2023 |
2022 |
||||||||||||
Cost of sales and services |
21 |
|||||||||||||||
Administrative expenses |
21 |
|||||||||||||||
In thousands of soles |
2024 |
2023 |
2022 |
|||||||||
Radioncologia S.A.C. (Radioncologia) |
||||||||||||
Laboratorio Cantella S.A.C. (Cantella) |
||||||||||||
R&R Patólogos Asociados S.A.C. (R&R) |
||||||||||||
Servimédicos S.A.C. (Servimédicos) |
||||||||||||
Clínica Bellavista S.A.C. (Bellavista) |
||||||||||||
Patología Oncológica S.A.C. |
||||||||||||
Oncogenomics S.A.C. |
||||||||||||
Promotora Médica Las Américas S.A. |
||||||||||||
Instituto de Cancerología S.A. |
||||||||||||
Laboratorio Médico Las Américas Ltda. |
||||||||||||
Oncomedica S.A. |
||||||||||||
Hospital y Clinica OCA S.A. de C.V. |
||||||||||||
Dentegra Seguros Dentales S.A. |
— | |||||||||||
Total goodwill |
||||||||||||
In percent |
2024 |
2023 |
2022 | |||
For companies located in Peru |
||||||
Terminal value growth rate |
||||||
Discount rate – After-tax |
||||||
Discount rate – Pre-tax |
||||||
For companies located in Colombia |
||||||
Terminal value growth rate |
||||||
Discount rate – After-tax |
||||||
Discount rate – Pre-tax |
||||||
For companies located in Mexico |
||||||
Terminal value growth rate |
||||||
Discount rate – After-tax |
||||||
Discount rate – Pre-tax |
| • | The terminal growth rate represents Management’s estimate of the long-term growth of each CGU, taking into account past and future growth and external sources of information. |
| • | Projected cash flows are based on Management’s operating EBITDA profit projections for a period of five years. |
EBITDA as a percentage of revenue | ||
Radioncologia S.A.C. (Radioncologia) |
||
Laboratorio Cantella S.A.C. (Cantella) |
||
R&R Patólogos Asociados S.A.C. (R&R) |
||
Servimédicos S.A.C. (Servimédicos) |
||
Clínica Bellavista S.A.C. (Bellavista) |
||
Patología Oncológica S.A.C. |
||
Oncogenomics S.A.C. |
||
Promotora Médica Las Américas S.A. |
||
Instituto de Cancerología S.A. |
||
Oncomedica S.A. |
||
Hospital y Clinica OCA S.A. de C.V. |
||
Dentegra Seguros Dentales S.A. |
| • | Projected cash flows include disbursements for capital investments. |
| • | The discount rates used to calculate the value in use for each Group’s CGU are an estimate that involves a market assessment of the time value of money and the risks inherent in each CGU where cash flows after-tax are generated taking into consideration the Group’s business plans. The nominal after-tax discount rate used for the impairment assessment was (after-tax) for the companies located in Peru, according to each Group’s CGU assessed as of December 31, 2024 (after-tax as of 2023 and 2022, respectively). For the companies located in Colombia (Promotora Médica Las Américas, Instituto de Cancerología and Laboratorio Médico Las Américas), the nominal after-tax discount rate was after-tax discount rate was |
| • | Projected cash flows include estimates of the revenue increase of each of the healthcare services at each CGU (Radioncología, Bellavista, Servimédicos, Cantella, Promotora Médica Las Américas, Instituto de Cancerología and Laboratorio Médico Las Américas), rates and gross margins. |
| • | The trademark has been allocated to the Group’s CGUs as follows: |
In thousands of soles |
2024 |
2023 |
2022 |
|||||||||
Hospital y Clinica OCA S.A. de C.V. |
||||||||||||
Dentegra Seguros Dentales S.A. |
— | |||||||||||
Promotora Médica Las Américas S.A. |
||||||||||||
Instituto de Cancerología S.A. |
||||||||||||
Laboratorio Médico Las Américas Ltda. |
||||||||||||
Clínica Portoazul S.A. |
||||||||||||
Oncomedica S.A. |
||||||||||||
Oncogenomics S.A.C. |
||||||||||||
Total trademarks |
||||||||||||
| • | The customer relationship has been allocated to the Group’s CGUs net of amortization as follows: |
In thousands of soles |
2024 |
2023 |
2022 |
|||||||||
Hospital y Clínica OCA S.A. de C.V. |
||||||||||||
Promotora Médica Las Américas S.A. |
||||||||||||
Patología Oncológica S.A.C. |
||||||||||||
Oncogenomics S.A.C. |
||||||||||||
Total customer relationship |
||||||||||||
After tax discount rate |
Terminal value growth rate |
|||||||||||||||||||||||
2024 |
2023 |
2022 |
2024 |
2023 |
2022 |
|||||||||||||||||||
Radioncologia S.A.C. |
( |
) | Indet. | ( |
) | |||||||||||||||||||
Laboratorio Cantella S.A.C. |
Indet. | Indet. | Indet. | |||||||||||||||||||||
R&R Patólogos Asociados S.A.C. |
Indet. | ( |
) | Indet. | ||||||||||||||||||||
Servimédicos S.A.C. |
— | ( |
) | Indet. | ||||||||||||||||||||
Clínica Bellavista S.A.C. |
( |
) | Indet. | ( |
) | |||||||||||||||||||
Patología Oncológica S.A.C. |
Indet. | Indet. | ||||||||||||||||||||||
Oncogenomics S.A.C. |
Indet. | ( |
) | |||||||||||||||||||||
Promotora Médica Las Américas S.A. |
Indet. | Indet. | ||||||||||||||||||||||
Instituto de Cancerología S.A. |
( |
) | ( |
) | ( |
) | ||||||||||||||||||
Laboratorio Médico Las Américas Ltda. |
— | — | — | — | ( |
) | ||||||||||||||||||
Oncomedica S.A. |
||||||||||||||||||||||||
Hospital y Clinica OCA S.A. de C.V. |
( |
) | ( |
) | ( |
) | ||||||||||||||||||
Dentegra Seguros Dentales S.A |
— | ( |
) | ( |
) | — | ||||||||||||||||||
13. |
Leases |
Right-of-use |
||||||||||||||||||||||||||||
In thousands of soles |
Note |
Lands |
Buildings and facilities |
Medical equipment and other |
Vehicles |
Furniture and fixture |
Total |
|||||||||||||||||||||
Balance at January 1, 2022 |
||||||||||||||||||||||||||||
Additions of right-of-use |
— | — | ||||||||||||||||||||||||||
Acquired through business combinations |
1.C.iii |
— | — | — | ||||||||||||||||||||||||
Transfers to property, furniture and equipment |
— | — | ( |
) | — | — | ( |
) | ||||||||||||||||||||
Annual depreciation (c) |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||
Write-off (b) |
— | ( |
) | — | — | — | ( |
) | ||||||||||||||||||||
Exchange difference |
— | ( |
) | ( |
) | ( |
) | — | ( |
) | ||||||||||||||||||
Balance at December 31, 2022 |
||||||||||||||||||||||||||||
Balance at January 1, 2023 |
||||||||||||||||||||||||||||
Additions of right-of-use |
— | — | — | |||||||||||||||||||||||||
Transfers to property, furniture and equipment |
— | — | ( |
) | — | — | ( |
) | ||||||||||||||||||||
Annual depreciation (c) |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||
Write-off (b) |
— | ( |
) | ( |
) | — | — | ( |
) | |||||||||||||||||||
Exchange difference |
— | — | ||||||||||||||||||||||||||
Balance at December 31, 2023 |
||||||||||||||||||||||||||||
Balance at January 1, 2024 |
||||||||||||||||||||||||||||
Additions of right-of-use |
— | — | — | |||||||||||||||||||||||||
Transfers to property, furniture and equipment |
— | — | ( |
) | — | — | ( |
) | ||||||||||||||||||||
Annual depreciation (c) |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||
Write-off (b) |
— | — | ( |
) | — | — | ( |
) | ||||||||||||||||||||
Exchange difference |
— | ( |
) | ( |
) | ( |
) | — | ( |
) | ||||||||||||||||||
Balance at December 31, 2024 |
||||||||||||||||||||||||||||
| (a) | In 2024, the additions of the Group mainly correspond to new lease agreements for use of commercial offices and equipment for medical use. The Group recognized S/ right-of-use |
| (b) | In 2023, it corresponds mainly to the physical inventory of fixed assets of the Group with a cost of S/ |
| (c) | The depreciation recognized in the consolidated statement of profit or loss and other comprehensive income includes: |
In thousands of soles |
Note |
2024 |
2023 |
2022 |
||||||||||||
Cost of sales and services |
21 |
|||||||||||||||
Selling expenses |
21 |
|||||||||||||||
Administrative expenses |
21 |
|||||||||||||||
i. |
Lease liabilities |
In thousands of soles |
Note |
2024 |
2023 |
2022 |
||||||||||||
Balance at January 1 |
||||||||||||||||
Additions |
||||||||||||||||
Acquired through business combination |
1.C.iii |
— | — | |||||||||||||
Interest expense |
||||||||||||||||
Leases prepayment penalty |
— | — | ||||||||||||||
Payments |
( |
) | ( |
) | ( |
) | ||||||||||
Penalty paid for leases prepayment |
— | — | ( |
) | ||||||||||||
Lease contracts cancelled |
— | ( |
) | ( |
) | |||||||||||
Exchange difference |
( |
) | ( |
) | ||||||||||||
Balance at December 31 |
||||||||||||||||
Current |
||||||||||||||||
Non-current |
||||||||||||||||
14. |
Deferred Income Tax |
In thousands of soles |
Balances as of January 1 |
Recorded in the profit or loss for the year |
Exchange difference |
Recorded in other comprehensive income |
Balances as of December 31 |
Deferred tax assets |
Deferred tax liabilities |
|||||||||||||||||||||
2024 |
||||||||||||||||||||||||||||
Tax losses |
( |
) | — | |||||||||||||||||||||||||
Loss for impairment of trade receivables |
( |
) | ( |
) | — | |||||||||||||||||||||||
Provision for unpaid vacations and annual performance bonuses |
( |
) | ( |
) | — | — | ||||||||||||||||||||||
Trade accounts payable |
( |
) | — | |||||||||||||||||||||||||
Derivative financial instruments |
( |
) | ( |
) | — | |||||||||||||||||||||||
Provisions |
( |
) | ( |
) | — | |||||||||||||||||||||||
Intangibles |
( |
) | — | ( |
) | ( |
) | |||||||||||||||||||||
Investments in associates and others |
( |
) | ( |
) | — | ( |
) | ( |
) | ( |
) | |||||||||||||||||
Loans and borrowings |
( |
) | ( |
) | — | |||||||||||||||||||||||
Property, furniture and equipment |
( |
) | ( |
) | — | ( |
) | ( |
) | ( |
) | |||||||||||||||||
Others |
( |
) | ( |
) | — | ( |
) | |||||||||||||||||||||
Net tax |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||
In thousands of soles |
Balances as of January 1 |
Recorded in the profit or loss for the year |
Exchange difference |
Business combination |
Rec ord edin other comprehensive income |
Balances as of December 31 |
Deferred tax assets |
Deferred tax liabilities |
||||||||||||||||||||||||
2023 |
||||||||||||||||||||||||||||||||
Tax losses |
— | |||||||||||||||||||||||||||||||
Loss for impairment of trade receivables |
— | — | ||||||||||||||||||||||||||||||
Provision for unpaid vacations and annual performance bonuses |
||||||||||||||||||||||||||||||||
Trade accounts payable |
( |
) | ( |
) | — | ( |
) | ( |
) | |||||||||||||||||||||||
Derivative financial instruments |
— | ( |
) | |||||||||||||||||||||||||||||
Provisions |
— | |||||||||||||||||||||||||||||||
Intangibles |
( |
) | ( |
) | ( |
) | — | ( |
) | — | ( |
) | ||||||||||||||||||||
Investments in associates and others |
( |
) | ( |
) | ( |
) | — | ( |
) | ( |
) | ( |
) | |||||||||||||||||||
Loans and borrowings |
— | — | ||||||||||||||||||||||||||||||
Property, furniture and equipment |
( |
) | ( |
) | ( |
) | ( |
) | — | ( |
) | ( |
) | ( |
) | |||||||||||||||||
Others |
( |
) | ( |
) | — | ( |
) | ( |
) | |||||||||||||||||||||||
Net tax |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||||
In thousands of soles |
Balances as of January 1 |
Recorded in the profit or loss for the year |
Exchange difference |
Shareholder´s downstream merger |
Business combination |
Recorded in other comprehensive income |
Balances as of December 31 |
Deferred tax assets |
Deferred tax liabilities |
|||||||||||||||||||||||||||
2022 |
||||||||||||||||||||||||||||||||||||
Tax losses |
( |
) | — | — | ||||||||||||||||||||||||||||||||
Loss for impairment of trade receivables |
( |
) | ( |
) | — | — | ||||||||||||||||||||||||||||||
Provision for unpaid vacations and annual performance bonuses |
( |
) | — | — | ||||||||||||||||||||||||||||||||
Trade accounts payable |
( |
) | — | — | ||||||||||||||||||||||||||||||||
Derivative financial instruments |
— | — | — | ( |
) | — | ||||||||||||||||||||||||||||||
Provisions |
( |
) | — | — | ||||||||||||||||||||||||||||||||
Intangibles |
( |
) | — | ( |
) | — | ( |
) | — | ( |
) | |||||||||||||||||||||||||
Investments in associates and others |
( |
) | — | — | — | ( |
) | ( |
) | — | ||||||||||||||||||||||||||
Loans and borrowings |
( |
) | ( |
) | — | — | ( |
) | ||||||||||||||||||||||||||||
Property, furniture and equipment |
( |
) | ( |
) | — | ( |
) | — | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||
Others |
( |
) | ( |
) | — | — | — | ( |
) | |||||||||||||||||||||||||||
Net tax |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||||||||||
15. |
Loans and Borrowings |
Outstanding balances |
||||||||||||||||||||||||||||||||||||||||
2024 |
2023 |
2022 |
||||||||||||||||||||||||||||||||||||||
In thousands of soles |
Type of obligation |
Maturity |
Interest rate |
Currency |
Face value |
Carrying amount |
Face value |
Carrying amount |
Face value |
Carrying amount |
||||||||||||||||||||||||||||||
Entity |
||||||||||||||||||||||||||||||||||||||||
Banco Davivienda |
Bank loan | |||||||||||||||||||||||||||||||||||||||
| % | — | — | ||||||||||||||||||||||||||||||||||||||
| Government guaranteed loan |
|
% | ||||||||||||||||||||||||||||||||||||||
| % | ||||||||||||||||||||||||||||||||||||||||
| % | ||||||||||||||||||||||||||||||||||||||||
| % | ||||||||||||||||||||||||||||||||||||||||
| % | ||||||||||||||||||||||||||||||||||||||||
| % | — | — | ||||||||||||||||||||||||||||||||||||||
% |
— | — | — |
— |
||||||||||||||||||||||||||||||||||||
% |
— | — | — |
— |
||||||||||||||||||||||||||||||||||||
Bank loan |
% |
— | — | — |
— |
|||||||||||||||||||||||||||||||||||
% |
— | — | — |
— |
||||||||||||||||||||||||||||||||||||
% |
— | — | — |
— |
||||||||||||||||||||||||||||||||||||
| — | — | — |
— |
|||||||||||||||||||||||||||||||||||||
% |
— | — | — |
— |
||||||||||||||||||||||||||||||||||||
| — | — | — |
— |
|||||||||||||||||||||||||||||||||||||
Banco de Bogotá |
Bank loan |
% | — | — | ||||||||||||||||||||||||||||||||||||
| % | — | — | ||||||||||||||||||||||||||||||||||||||
| % | ||||||||||||||||||||||||||||||||||||||||
| % | — | — | — | — | ||||||||||||||||||||||||||||||||||||
| % | — | — | — | — | ||||||||||||||||||||||||||||||||||||
| % | — | — | ||||||||||||||||||||||||||||||||||||||
Banco de Occidente |
Bank loan | % | — | — | ||||||||||||||||||||||||||||||||||||
| % | — | — | — | — | ||||||||||||||||||||||||||||||||||||
| % | — | — | — | — | ||||||||||||||||||||||||||||||||||||
| % | — | — | — | — | ||||||||||||||||||||||||||||||||||||
| % | — | — | — | — | ||||||||||||||||||||||||||||||||||||
| % | — | — | ||||||||||||||||||||||||||||||||||||||
Outstanding balances |
||||||||||||||||||||||||||||||||||||
2024 |
2023 |
2022 |
||||||||||||||||||||||||||||||||||
In thousands of soles |
Type of obligation |
Maturity |
Interest rate |
Currency |
Face value |
Carrying amount |
Face value |
Carrying amount |
Face value |
Carrying amount |
||||||||||||||||||||||||||
Bancolombia |
% | |||||||||||||||||||||||||||||||||||
| — | — | |||||||||||||||||||||||||||||||||||
| % | — | — | — | — | ||||||||||||||||||||||||||||||||
| % | — | — | — | — | ||||||||||||||||||||||||||||||||
| % | — | — | — | — | ||||||||||||||||||||||||||||||||
| % | — | — | — | — | ||||||||||||||||||||||||||||||||
DT F |
% | — | — | — | — | |||||||||||||||||||||||||||||||
| Bank loan | % | — | — | — | — | |||||||||||||||||||||||||||||||
| % | — | — | ||||||||||||||||||||||||||||||||||
| % | — | — | — | — | ||||||||||||||||||||||||||||||||
| % | — | — | — | — | ||||||||||||||||||||||||||||||||
| % | — | — | — | — | ||||||||||||||||||||||||||||||||
| % | — | — | — | — | ||||||||||||||||||||||||||||||||
| % | — | — | — | — | ||||||||||||||||||||||||||||||||
| % | — | — | ||||||||||||||||||||||||||||||||||
| % | — | — | — | — | ||||||||||||||||||||||||||||||||
| % | — | — | — | — | ||||||||||||||||||||||||||||||||
| % | — | — | — | — | ||||||||||||||||||||||||||||||||
| % | — | — | ||||||||||||||||||||||||||||||||||
| % | — | — | — | — | ||||||||||||||||||||||||||||||||
| Other financing | % | |||||||||||||||||||||||||||||||||||
Banco Citibank Colombia |
Bank loan | % | — | — | — | — | ||||||||||||||||||||||||||||||
| % | — | — | — | — | ||||||||||||||||||||||||||||||||
| % | — | — | ||||||||||||||||||||||||||||||||||
| % | — | — | ||||||||||||||||||||||||||||||||||
| % | — | — | ||||||||||||||||||||||||||||||||||
| — | — | — | — | |||||||||||||||||||||||||||||||||
| % | — | — | ||||||||||||||||||||||||||||||||||
Itaú Corpbanca Colombia S.A. |
Bank loan | % | ||||||||||||||||||||||||||||||||||
| % | — | — | ||||||||||||||||||||||||||||||||||
| % | — | — | — | — | ||||||||||||||||||||||||||||||||
| % | ||||||||||||||||||||||||||||||||||||
Boston Scientific Colombia lt |
% | |||||||||||||||||||||||||||||||||||
JP Morgan Bank |
% | — | — | — | — | |||||||||||||||||||||||||||||||
Banco de Crédito del Perú |
Bank loan | % | — | — | — | — | ||||||||||||||||||||||||||||||
| % | — | — | — | — | ||||||||||||||||||||||||||||||||
| % | — | — | — | — | ||||||||||||||||||||||||||||||||
| % | — | — | — | — | ||||||||||||||||||||||||||||||||
| % | — | — | — | — | ||||||||||||||||||||||||||||||||
| Government guaranteed loan |
% | — | — | — | — | |||||||||||||||||||||||||||||||
| % | — | — | — | — | ||||||||||||||||||||||||||||||||
Outstanding balances |
||||||||||||||||||||||||||||||||||||||
2024 |
2023 |
2022 |
||||||||||||||||||||||||||||||||||||
In thousands of soles |
Type of obligation |
Maturity |
Interest rate |
Currency |
Face value |
Carrying amount |
Face value |
Carrying amount |
Face value |
Carrying amount |
||||||||||||||||||||||||||||
Scotiabank Perú S.A.A. |
Bank loan | % | — | — | — | — | ||||||||||||||||||||||||||||||||
| % | — | — | — | — | ||||||||||||||||||||||||||||||||||
| % | — | — | — | — | ||||||||||||||||||||||||||||||||||
| Other financing | % | |||||||||||||||||||||||||||||||||||||
| Bank loan | % | — | — | — | — | |||||||||||||||||||||||||||||||||
| % | — | — | — | — | ||||||||||||||||||||||||||||||||||
| % | — | — | — | — | ||||||||||||||||||||||||||||||||||
| % | — | — | — | — | ||||||||||||||||||||||||||||||||||
Banco BBVA Continental |
Bank loan | % | — | — | — | — | ||||||||||||||||||||||||||||||||
| % | — | — | — | — | ||||||||||||||||||||||||||||||||||
| % | — | — | — | — | ||||||||||||||||||||||||||||||||||
| % | — | — | — | — | ||||||||||||||||||||||||||||||||||
| % | — | — | — | — | ||||||||||||||||||||||||||||||||||
Banco ITAU |
% | — | — | — | — | |||||||||||||||||||||||||||||||||
Banco Interamericano de Finanzas |
% | — | — | — | — | |||||||||||||||||||||||||||||||||
| % | — | — | — | — | ||||||||||||||||||||||||||||||||||
| % | — | — | — | — | ||||||||||||||||||||||||||||||||||
| % | — | — | — | — | ||||||||||||||||||||||||||||||||||
| % | — | — | — | — | ||||||||||||||||||||||||||||||||||
| % | — | — | — | — | ||||||||||||||||||||||||||||||||||
| % | — | — | — | — | ||||||||||||||||||||||||||||||||||
| % | — | — | — | — | ||||||||||||||||||||||||||||||||||
Banco Internacional del Perú S.A.A. |
2024 |
% | — | — | — | — | ||||||||||||||||||||||||||||||||
| % | — | — | — | — | ||||||||||||||||||||||||||||||||||
| % | — | — | — | — | ||||||||||||||||||||||||||||||||||
| % | — | — | — | — | ||||||||||||||||||||||||||||||||||
| Bank loan | % | — | — | — | — | |||||||||||||||||||||||||||||||||
Banco Pichincha |
% | — | — | |||||||||||||||||||||||||||||||||||
| % | — | — | — | — | ||||||||||||||||||||||||||||||||||
| % | — | — | — | — | ||||||||||||||||||||||||||||||||||
Banco Citibank |
% | — | — | — | — | |||||||||||||||||||||||||||||||||
| % | — | — | — | — | ||||||||||||||||||||||||||||||||||
| % | — | — | — | — | ||||||||||||||||||||||||||||||||||
| % | — | — | — | — | ||||||||||||||||||||||||||||||||||
| % | — | — | — | — | ||||||||||||||||||||||||||||||||||
| % | — | — | — | — | ||||||||||||||||||||||||||||||||||
Outstanding balances |
||||||||||||||||||||||||||||||||||||
2024 |
2023 |
2022 |
||||||||||||||||||||||||||||||||||
In thousands of soles |
Type of obligation |
Maturity |
Interest rate |
Currency |
Face value |
Carrying amount |
Face value |
Carrying amount |
Face value |
Carrying amount |
||||||||||||||||||||||||||
Banco GNB |
Bank loan | % | ||||||||||||||||||||||||||||||||||
Banco Santander México, HSBC Mexico, Multiva and Genaro Levinson Marcovich |
Loan | % | — | — | — | — | ||||||||||||||||||||||||||||||
BBVA Bancomer |
Bank loan | % | — | — | — | — | ||||||||||||||||||||||||||||||
Secured bonds issues |
Senior notes | % | — | — | ||||||||||||||||||||||||||||||||
| % | — | — | ||||||||||||||||||||||||||||||||||
Banco Santander México, HSBC and Citibank |
Bank loan | % | — | — | ||||||||||||||||||||||||||||||||
| % | — | — | ||||||||||||||||||||||||||||||||||
| % | — | — | ||||||||||||||||||||||||||||||||||
HSBC México |
Bank loan | % | — | — | — | — | ||||||||||||||||||||||||||||||
Total |
||||||||||||||||||||||||||||||||||||
Current |
— |
— |
||||||||||||||||||||||||||||||||||
Non-current |
— |
— |
||||||||||||||||||||||||||||||||||
| (a) | Bank loans with covenants |
| • | The Net Leverage Ratio for the Issuer and its Restricted Subsidiaries on a consolidated basis is less than (i) |
| • | The Interest Coverage Ratio for the Issuer and its Restricted Subsidiaries on a consolidated basis is at least |
| • | The Net Leverage Ratio for the Issuer and its Restricted Subsidiaries on a consolidated basis is less than (i) to |
| • | The Interest Coverage Ratio for the Issuer and its Restricted Subsidiaries on a consolidated basis is at least i) |
| • | The consolidated leverage ratio is less than (i) |
| • | The consolidated interest coverage ratio is at least |
| • | The consolidated leverage ratio to be less than (i) |
| • | The consolidated interest coverage ratio is at least (i) |
| • | The minimum net worth shall not permit, as of the end of each fiscal quarter, that the total assets minus the total liabilities of any subsidiary of Auna Colombia S.A.S. that is an “institución prestadora de servicios de salud” to be less than 50% of the paid-in capital of such subsidiary. |
| • | The consolidated leverage ratio is less than (i) |
| • | The consolidated interest coverage ratio is greater than (i) |
| • | Maintain a debt service ratio equal to or greater than |
| • | Maintain a consolidated leverage ratio, defined as the ratio of our net debt / EBITDA, less than or equal to |
| • | Maintain an interest coverage ratio equal to or greater than |
| • | Maintain a debt service ratio equal to or greater than |
| (b) | Reconciliation of movement in liabilities to cash flows arising from financing activities: |
In thousands of soles |
Financial loan |
Deferred income |
Lease liabilities |
Derivatives premiums payable |
Accounts payable related with exchange |
Share capital/ premium |
Retained earnings (losses) |
Translation reserve |
Merge reserve |
Non- controlling interest |
Total |
|||||||||||||||||||||||||||||||||
Balance as of January 1, 2024 |
( |
) | ||||||||||||||||||||||||||||||||||||||||||
Changes in cash flows from financing |
||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of common stock in initial public offering, net of issuance costs |
— | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||
Payments of initial public offering costs |
— | — | — | — | — | ( |
) | — | — | — | — | ( |
) | |||||||||||||||||||||||||||||||
Proceeds from loans and borrowings |
— | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||
Payment for borrowings from financial obligations |
( |
) | — | — | — | — | — | — | — | — | — | ( |
) | |||||||||||||||||||||||||||||||
Payment for costs of Extinguishment of debt |
— | — | — | — | ( |
) | — | — | — | — | — | ( |
) | |||||||||||||||||||||||||||||||
Payment of lease liabilities |
— | — | ( |
) | — | — | — | — | — | — | — | ( |
) | |||||||||||||||||||||||||||||||
Trust funds |
— | — | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||
Interest paid |
( |
) | — | — | — | — | — | — | — | — | — | ( |
) | |||||||||||||||||||||||||||||||
Penalty paid for debt prepayment |
— | — | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||
Acquisition of non-controlling interest |
— | — | — | — | — | — | — | ( |
) | ( |
) | ( |
) | |||||||||||||||||||||||||||||||
Dividends paid |
— | — | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||
Payment for derivatives premiums |
— | — | — | ( |
) | — | — | — | — | — | — | ( |
) | |||||||||||||||||||||||||||||||
Total changes from financing cash flows |
( |
) |
— |
( |
) |
( |
) |
( |
) |
— |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||||||||||
Effect of changes in foreign exchange rates |
( |
) |
( |
) |
( |
) |
( |
) |
— |
— |
— |
( |
) |
— |
— |
( |
) | |||||||||||||||||||||||||||
Changes arising from obtaining control of new subsidiaries |
— |
— |
— |
— |
— |
— |
— |
— |
— |
— |
— |
|||||||||||||||||||||||||||||||||
Changes in fair value |
— | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||
Total equity-related other changes |
— | — | — | — | — | ( |
) | — | ( |
) | ||||||||||||||||||||||||||||||||||
Other changes |
||||||||||||||||||||||||||||||||||||||||||||
Assets acquired through new leases |
— | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||
Acquisition of derivative with premiums financing |
— | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||
Lease contracts cancelled |
— | — | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||
Debt exchange |
— | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||
Interest expense |
( |
) | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||
Transaction costs related to loans and borrowings |
( |
) | — | — | — | — | — | — | — | — | — | ( |
) | |||||||||||||||||||||||||||||||
Unwind of derivative financial instruments net of premiums payable |
— | — | — | ( |
) | — | — | — | — | — | — | ( |
) | |||||||||||||||||||||||||||||||
Balance as of December 31, 2024 |
( |
) |
( |
) |
||||||||||||||||||||||||||||||||||||||||
In thousands of soles |
Financial loan |
Deferred income |
Lease liabilities |
Derivatives premiums payable |
Trust funds |
Share capital/ premium |
Retained earnings (losses) |
Merge reserve |
Non-controlling interest |
Total |
||||||||||||||||||||||||||||||
Balance as of January 1, 2023 |
( |
) | ( |
) | ||||||||||||||||||||||||||||||||||||
Changes in cash flows from financing |
||||||||||||||||||||||||||||||||||||||||
Proceeds from loans and borrowings |
— | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||
Payment for borrowings from financial obligations |
( |
) | — | — | — | — | — | — | — | — | ( |
) | ||||||||||||||||||||||||||||
Payment of lease liabilities |
— | — | ( |
) | — | — | — | — | — | — | ( |
) | ||||||||||||||||||||||||||||
Trust funds |
— | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||
Interest paid |
( |
) | — | — | — | — | — | — | — | — | ( |
) | ||||||||||||||||||||||||||||
Penalty paid for debt prepayment |
( |
) | — | — | — | — | — | — | — | — | ( |
) | ||||||||||||||||||||||||||||
Contributions from non-controlling shareholder |
— | — | — | — | — | — | — | ( |
) | |||||||||||||||||||||||||||||||
Dividends paid |
— | — | — | — | — | — | — | — | ( |
) | ( |
) | ||||||||||||||||||||||||||||
Payment for derivatives premiums |
— | — | — | ( |
) | — | — | — | — | — | ( |
) | ||||||||||||||||||||||||||||
Total changes from financing cash flows |
( |
) |
— |
( |
) |
( |
) |
— |
— |
( |
) |
( |
) |
( |
) | |||||||||||||||||||||||||
Effect of changes in foreign exchange rates |
( |
) |
— |
— |
— |
— |
||||||||||||||||||||||||||||||||||
Changes arising from obtaining control of new subsidiaries |
— |
— |
— |
— |
— |
— |
— |
— |
— |
— |
||||||||||||||||||||||||||||||
Changes in fair value |
— | — | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||
Total equity-related other changes |
— | — | — | — | — | ( |
) | ( |
) | ( |
) | ( |
) | |||||||||||||||||||||||||||
Other changes |
||||||||||||||||||||||||||||||||||||||||
Assets acquired through new leases |
— | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||
Acquisition of derivative with premiums financing |
— | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||
Lease contracts cancelled |
— | — | ( |
) | — | — | — | — | — | — | ( |
) | ||||||||||||||||||||||||||||
Debt exchange |
— | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||
Interest expense |
( |
) | ( |
) | — | — | — | — | ||||||||||||||||||||||||||||||||
Transaction costs related to loans and borrowings |
( |
) | — | — | — | — | — | — | — | — | ( |
) | ||||||||||||||||||||||||||||
Financial debt prepayment penalty |
— | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||
Balance as of December 31, 2023 |
— |
( |
) |
|||||||||||||||||||||||||||||||||||||
In thousands of soles |
Financial loan |
Deferred income |
Lease liabilities |
Derivatives premiums payable |
Share capital/ premium |
Retained earnings (losses) |
Merge reserve |
Non- controlling interest |
Total |
|||||||||||||||||||||||||||
Balance as of January 1, 2022 |
( |
) | ( |
) | ||||||||||||||||||||||||||||||||
Changes in cash flows from financing |
||||||||||||||||||||||||||||||||||||
Proceeds from contributions from non-controlling shareholder |
— | — | — | — | — | — | ||||||||||||||||||||||||||||||
Proceeds from loans and borrowings |
— | — | — | — | — | — | — | |||||||||||||||||||||||||||||
Payment for borrowings from financial obligations |
( |
) | — | — | — | — | — | — | — | ( |
) | |||||||||||||||||||||||||
Payment of lease liabilities |
— | — | ( |
) | — | — | — | — | — | ( |
) | |||||||||||||||||||||||||
Interest paid |
( |
) | — | — | — | — | — | — | — | ( |
) | |||||||||||||||||||||||||
Penalty paid for debt prepayment |
— | — | ( |
) | — | — | — | — | — | ( |
) | |||||||||||||||||||||||||
Payment for derivatives premiums |
— | — | — | ( |
) | — | — | — | — | ( |
) | |||||||||||||||||||||||||
Total changes from financing cash flows |
— |
( |
) |
( |
) |
— |
— |
|||||||||||||||||||||||||||||
Effect of changes in foreign exchange rates |
( |
) |
( |
) |
( |
) |
— |
— |
— |
— |
— |
( |
) | |||||||||||||||||||||||
Changes arising from obtaining control of new subsidiaries |
— |
— |
— |
— |
( |
) |
( |
) | ||||||||||||||||||||||||||||
Changes in fair value |
( |
) | — | — | — | — | — | — | — | |||||||||||||||||||||||||||
Total equity-related other changes |
— | — | — | — | — | ( |
) | ( |
) | ( |
) | ( |
) | |||||||||||||||||||||||
Other changes |
||||||||||||||||||||||||||||||||||||
Assets acquired through new leases |
— | — | — | — | — | — | — | |||||||||||||||||||||||||||||
Acquisition of derivative with premiums financing |
— | — | — | — | — | — | — | |||||||||||||||||||||||||||||
Lease contracts cancelled |
— | — | ( |
) | — | — | — | — | — | ( |
) | |||||||||||||||||||||||||
Interest expense |
( |
) | — | — | — | — | ||||||||||||||||||||||||||||||
Transaction costs related to loans and borrowings |
( |
) | — | — | — | — | — | — | — | ( |
) | |||||||||||||||||||||||||
Financial debt prepayment penalty |
— | — | — | — | — | — | — | |||||||||||||||||||||||||||||
Balance as of December 31, 2022 |
( |
) |
||||||||||||||||||||||||||||||||||
16. |
Trade Accounts Payable |
In thousands of soles |
2024 |
2023 |
2022 |
|||||||||
Soles |
||||||||||||
U.S. dollars |
||||||||||||
COP |
||||||||||||
Euros |
— | — | ||||||||||
MXN |
||||||||||||
Current |
||||||||||||
Non-current |
||||||||||||
17. |
Other Accounts Payable |
In thousands of soles |
Note |
2024 |
2023 |
2022 |
||||||||||||
Current |
||||||||||||||||
Employee benefits (c) |
||||||||||||||||
Taxes payable |
||||||||||||||||
Derivatives Fx premiums and accounts payable for “unwind” (b) |
||||||||||||||||
Constructions in progress and medical equipment payable |
||||||||||||||||
Deposits in guarantee |
||||||||||||||||
Commissions payable (a) |
||||||||||||||||
Contingent consideration (d) |
1.C.iii |
— | ||||||||||||||
Account payables to former shareholder (d) |
1.C.ii, iii |
— | ||||||||||||||
Other accounts payable (e) |
||||||||||||||||
Non-current |
||||||||||||||||
Employee benefits (c) |
||||||||||||||||
Derivatives Fx premiums and accounts payable for “unwind” (b) |
||||||||||||||||
Put liability |
1.C.iii |
— | ||||||||||||||
Account payables to former shareholder |
1.C.ii,iii |
— | ||||||||||||||
| (a) | Corresponds to the sales commissions payable for the sales of corporate and individual oncologic healthcare plans. |
| (b) | Derivatives premiums financing |
In thousands of soles |
Maturity |
Currency of origin |
Annual nominal interest rate |
Current portion |
Non-current portion |
December 31, 2024 |
||||||||||||||||||
Citibank |
2025 | S/ | % | |||||||||||||||||||||
Citibank |
2028 | S/ | % | |||||||||||||||||||||
Citibank |
2026 | S/ | % | |||||||||||||||||||||
Citibank |
2028 | S/ | % | |||||||||||||||||||||
Deutsche Bank |
2029 | S/ | % | |||||||||||||||||||||
Santander Bank |
2026 | S/ | % | |||||||||||||||||||||
In thousands of soles |
Maturity |
Currency of origin |
Annual nominal interest rate |
Current portion |
Non-current portion |
December 31, 2023 |
||||||||||||||||||
Citibank |
2025 | S/ | % | |||||||||||||||||||||
Citibank |
2028 | S/ | % | |||||||||||||||||||||
Citibank |
2026 | S/ | % | |||||||||||||||||||||
Citibank |
2028 | S/ | % | |||||||||||||||||||||
Citibank |
2024 | S/ | % | |||||||||||||||||||||
Santander Bank |
2026 | S/ | % | |||||||||||||||||||||
In thousands of soles |
Maturity |
Currency of origin |
Annual nominal interest rate |
Current portion |
Non-current portion |
December 31, 2022 |
||||||||||||||||||
Goldman Sachs Bank |
2023 | S/ | % | — | ||||||||||||||||||||
Citibank |
2025 | S/ | % | — | ||||||||||||||||||||
Citibank |
2026 | S/ | % | |||||||||||||||||||||
In thousands of soles |
Maturity |
Currency of origin |
Annual nominal interest rate |
Current portion |
Non-current portion |
December 31, 2022 |
||||||||||||||||||
Goldman Sachs Bank |
2023 | S/ | % | — | ||||||||||||||||||||
— |
||||||||||||||||||||||||
| (c) | Corresponds to compensation and other short-term benefits payable to personnel of S/ |
In thousands of soles |
Note |
Seniority premium |
Retirement benefits |
Total |
||||||||||||
2024 |
||||||||||||||||
Balances as of January 1, 2024 |
— | |||||||||||||||
Included in profit or loss |
||||||||||||||||
Current service cost |
— | |||||||||||||||
Cancellation retirement benefits |
— | — | — | |||||||||||||
Interest cost |
— | |||||||||||||||
Benefits paid |
( |
) | — | ( |
) | |||||||||||
— |
||||||||||||||||
Included in OCI |
||||||||||||||||
Remeasurement of actuarial loss (gain) arising from: |
||||||||||||||||
Experience adjustment |
( |
) | — | ( |
) | |||||||||||
Financial assumptions |
( |
) | — | ( |
) | |||||||||||
Exchange difference |
( |
) | — | ( |
) | |||||||||||
( |
) |
— |
( |
) | ||||||||||||
Balance at December 31, 2024 |
— |
|||||||||||||||
Current |
||||||||||||||||
Non-current |
||||||||||||||||
In thousands of soles |
Note |
Seniority premium |
Retirement benefits |
Total |
||||||||||||
2023 |
||||||||||||||||
Balances as of January 1, 2023 |
||||||||||||||||
Business combination balances |
1.C.i |
— | ||||||||||||||
Included in profit or loss |
||||||||||||||||
Current service cost |
||||||||||||||||
Cancellation retirement benefits |
— | ( |
) | ( |
) | |||||||||||
Interest cost |
||||||||||||||||
Benefits paid |
( |
) | — | ( |
) | |||||||||||
( |
) |
|||||||||||||||
Included in OCI |
||||||||||||||||
Remeasurement of actuarial loss (gain) arising from: |
||||||||||||||||
Experience adjustment |
— | |||||||||||||||
Financial assumptions |
— | |||||||||||||||
Exchange difference |
||||||||||||||||
Balance at December 31, 2023 |
— |
|||||||||||||||
Current |
||||||||||||||||
Non-current |
||||||||||||||||
2022 |
||||||||||||||||
Business combination balances |
1.C. |
|||||||||||||||
Included in profit or loss |
||||||||||||||||
Current service cost |
||||||||||||||||
Interest cost |
||||||||||||||||
Benefits paid |
( |
) | ( |
) | ( |
) | ||||||||||
( |
) |
|||||||||||||||
Included in OCI |
||||||||||||||||
Remeasurement of actuarial loss (gain) arising from: |
||||||||||||||||
Experience adjustment |
( |
) | ||||||||||||||
Financial assumptions |
||||||||||||||||
Exchange difference |
( |
) | ( |
) | ( |
) | ||||||||||
( |
) |
|||||||||||||||
Balance at December 31, 2022 |
||||||||||||||||
Current |
||||||||||||||||
Non-current |
||||||||||||||||
In percent |
Seniority premium |
Retirement benefits |
||||
2024 |
||||||
Discount rate |
— | |||||
Salary growth rate |
— | |||||
Rate of increase in minimum wage |
— | |||||
2023 |
||||||
Discount rate |
— | |||||
Salary growth rate |
— | |||||
Rate of increase in minimum wage |
— | |||||
In percent |
Seniority premium |
Retirement benefits |
||||||
2022 |
||||||||
Discount rate |
% | % | ||||||
Salary growth rate |
% | % | ||||||
Rate of increase in minimum wage |
% | % | ||||||
In thousands of soles |
Seniority premium |
Retirement benefits |
Total |
|||||||||
2024 |
||||||||||||
Discount rate sensitivity analysis |
||||||||||||
Effect of an increase of |
||||||||||||
Defined Benefit Obligation impact |
( |
) | — | ( |
) | |||||||
Current Service Cost impact |
( |
) | — | ( |
) | |||||||
Effect of a decrease of |
||||||||||||
Defined Benefit Obligation impact |
— | |||||||||||
Current Service Cost impact |
— | |||||||||||
Salary increase rate sensitivity analysis |
||||||||||||
Effect of an increase of |
||||||||||||
Defined Benefit Obligation impact |
— | |||||||||||
Current Service Cost impact |
— | |||||||||||
Effect of a decrease of |
||||||||||||
Defined Benefit Obligation impact |
( |
) | — | ( |
) | |||||||
Current Service Cost impact |
— | |||||||||||
2023 |
||||||||||||
Discount rate sensitivity analysis |
||||||||||||
Effect of an increase of |
||||||||||||
Defined Benefit Obligation impact |
( |
) | — | ( |
) | |||||||
Current Service Cost impact |
( |
) | — | ( |
) | |||||||
Effect of a decrease of |
||||||||||||
Defined Benefit Obligation impact |
— | |||||||||||
Current Service Cost impact |
— | |||||||||||
Salary increase rate sensitivity analysis |
||||||||||||
Effect of an increase of |
||||||||||||
Defined Benefit Obligation impact |
— | |||||||||||
Current Service Cost impact |
— | |||||||||||
Effect of a decrease of |
||||||||||||
Defined Benefit Obligation impact |
( |
) | — | ( |
) | |||||||
Current Service Cost impact |
— | |||||||||||
2022 |
||||||||||||
Discount rate sensitivity analysis |
||||||||||||
Effect of an increase of |
||||||||||||
Defined Benefit Obligation impact |
||||||||||||
Current Service Cost impact |
||||||||||||
Effect of a decrease of |
||||||||||||
Defined Benefit Obligation impact |
( |
) | ( |
) | ( |
) | ||||||
Current Service Cost impact |
( |
) | ( |
) | ( |
) | ||||||
| (d) | As of December 31, 2024, the Group entered into agreements with selling shareholders who had the contingent consideration, generating short and long-term payment commitments; therefore, the “Contingent consideration” was reclassified to “Account payable to former shareholder” for an amount of S/ |
| (e) | As of December 31, 2024, 2023 and 2022, other accounts payable include collections in favor of Citibank del Perú S.A.A. for S/ |
18. |
Provisions |
In thousands of soles |
Note |
Outstanding claims reserve (i) |
Other provisions |
Total |
||||||||||||
As of January 1, 2022 |
||||||||||||||||
Annual provision |
— | |||||||||||||||
Paid during the year |
— | ( |
) | ( |
) | |||||||||||
Business combination balances |
1.C.ii |
— | ||||||||||||||
Exchange difference |
— | ( |
) | ( |
) | |||||||||||
As of December 31, 2022 |
||||||||||||||||
As of January 1, 2023 |
||||||||||||||||
Annual provision |
— | |||||||||||||||
Paid during the year |
( |
) | ( |
) | ( |
) | ||||||||||
Exchange difference |
— | |||||||||||||||
As of December 31, 2023 |
||||||||||||||||
As of January 1, 2024 |
||||||||||||||||
Annual provision |
— | |||||||||||||||
Paid during the year |
( |
) | ( |
) | ( |
) | ||||||||||
Exchange difference |
— | ( |
) | ( |
) | |||||||||||
As of December 31, 2024 |
||||||||||||||||
| (i) | Outstanding claims reserve represent the Group’s outstanding third-party obligations and do not include amounts related to the Group’s customers that are part of the insurance premium program. |
19. |
Equity |
A. |
Share capital |
Range of shareholding percentage |
Number of shareholders |
Participation percentage |
||||||
From |
||||||||
From |
||||||||
From |
||||||||
From |
||||||||
B. |
Other capital reserves |
C. |
Translation reserve |
D. |
Cost of hedging reserve |
E. |
Hedging reserve |
F. |
Merger and other reserves |
G. |
Non-controlling interests |
In thousands of soles |
Clínica Vallesur |
Clínica Miraflores |
PMLA |
Clinica Portoazul |
Oncomedica |
Total |
||||||||||||||||||
December 31, 2024 |
||||||||||||||||||||||||
NCI percentage |
% | % | % | % | % | |||||||||||||||||||
Net assets |
( |
) |
||||||||||||||||||||||
Net assets attributable to NCI |
( |
) |
||||||||||||||||||||||
Profit (loss) |
( |
) | ( |
) | ||||||||||||||||||||
Other Comprehensive Income (OCI) |
— | — | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||
Total comprehensive income |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||
Profit allocated to NCI |
( |
) | ( |
) | ||||||||||||||||||||
OCI allocated to NCI |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||
Total comprehensive income allocated to NCI |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||
In thousands of soles |
Clínica Vallesur |
Clínica Miraflores |
PMLA |
Clinica Portoazul |
Oncomedica |
Auna Salud |
Total |
|||||||||||||||||||||
December 31, 2023 |
||||||||||||||||||||||||||||
NCI percentage |
% | % | % | % | % | % | ||||||||||||||||||||||
Net assets |
( |
) |
( |
) |
||||||||||||||||||||||||
Net assets attributable to NCI |
( |
) |
( |
) |
||||||||||||||||||||||||
Profit (loss) |
( |
) | ( |
) | ||||||||||||||||||||||||
Other Comprehensive Income (OCI) |
— | — | ||||||||||||||||||||||||||
Total comprehensive income |
( |
) |
||||||||||||||||||||||||||
Profit allocated to NCI |
( |
) | ( |
) | ||||||||||||||||||||||||
OCI allocated to NCI |
||||||||||||||||||||||||||||
Total comprehensive income allocated to NCI |
( |
) |
||||||||||||||||||||||||||
In thousands of soles |
Clínica Vallesur |
Clínica Miraflores |
PMLA |
Clinica Portoazul |
Oncomedica |
Auna Salud |
Total |
|||||||||||||||||||||
December 31, 2022 |
||||||||||||||||||||||||||||
NCI percentage |
% | % | % | % | % | % | — | |||||||||||||||||||||
Net assets |
( |
) |
||||||||||||||||||||||||||
Net assets attributable to NCI |
( |
) |
||||||||||||||||||||||||||
Profit (loss) |
( |
) | ( |
) | ( |
) | ||||||||||||||||||||||
Other Comprehensive Income (OCI) |
— | — | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||
Total comprehensive income |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||
Profit allocated to NCI |
( |
) | ( |
) | ||||||||||||||||||||||||
OCI allocated to NCI |
— | — | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||
Total comprehensive income allocated to NCI |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||
20. |
Revenue |
A. |
Revenue streams |
In thousands of soles |
2024 |
2023 |
2022 |
|||||||||
Revenue from contracts with customers |
||||||||||||
Healthcare services (i) |
||||||||||||
Sale of medicines |
||||||||||||
Total revenue from contracts with customers |
||||||||||||
Insurance revenue |
||||||||||||
Total revenue |
||||||||||||
In thousands of soles |
2024 |
2023 |
2022 |
|||||||||
Oncology plans |
||||||||||||
General healthcare services plans |
||||||||||||
Total insurance revenue |
||||||||||||
Timing of revenue recognition |
||||||||||||
Products transferred at a point in time |
||||||||||||
Products and services transferred over time |
||||||||||||
Total revenue from contracts with customers |
||||||||||||
| (i) | The amounts reported in the Healthcare services revenue line item do not include revenue recognized for customers that are part of the Company’s insurance premium program. |
B. |
Disaggregation of revenue from contracts with customers |
In thousands of soles |
Oncosalud Peru |
Healthcare services segments |
Total |
|||||||||
For the year ended December 31, 2024 |
||||||||||||
Primary geographical markets |
||||||||||||
Peru |
||||||||||||
Colombia |
— | |||||||||||
Mexico |
— | |||||||||||
For the year ended December 31, 2023 |
||||||||||||
Primary geographical markets |
||||||||||||
Peru |
||||||||||||
Colombia |
— | |||||||||||
Mexico |
— | |||||||||||
For the year ended December 31, 2022 |
||||||||||||
Primary geographical markets |
||||||||||||
Peru |
||||||||||||
Colombia |
— | |||||||||||
C. |
Contract balances |
In thousands of soles |
Note |
2024 |
2023 |
2022 |
||||||||||
Trade accounts receivable |
5 |
|||||||||||||
Contract liabilities, which are included in “trade accounts payable” |
16 |
( |
) | ( |
) | ( |
) | |||||||
21. |
Cost of Sales and Services, Selling Expenses and Administrative Expenses |
In thousands of soles |
Note |
Cost of sales and services |
Selling expenses |
Administrative expenses |
Total |
|||||||||||||||||||||||||||||||||||||||||||||
2024 |
2023 |
2022 |
2024 |
2023 |
2022 |
2024 |
2023 |
2022 |
2024 |
2023 |
2022 |
|||||||||||||||||||||||||||||||||||||||
Medicines |
||||||||||||||||||||||||||||||||||||||||||||||||||
Auxiliary services and clinical laboratory |
||||||||||||||||||||||||||||||||||||||||||||||||||
Room service for inpatients |
||||||||||||||||||||||||||||||||||||||||||||||||||
Surgery fees |
||||||||||||||||||||||||||||||||||||||||||||||||||
Medical consultation fees |
||||||||||||||||||||||||||||||||||||||||||||||||||
Insurance contracts |
||||||||||||||||||||||||||||||||||||||||||||||||||
Personnel expenses (a) (c) |
||||||||||||||||||||||||||||||||||||||||||||||||||
Services provided by third parties (b) (c) |
||||||||||||||||||||||||||||||||||||||||||||||||||
Depreciation |
11, 13 |
|||||||||||||||||||||||||||||||||||||||||||||||||
Amortization |
12 |
|||||||||||||||||||||||||||||||||||||||||||||||||
Other management charges (c) |
||||||||||||||||||||||||||||||||||||||||||||||||||
Tax expenses |
||||||||||||||||||||||||||||||||||||||||||||||||||
| (a) | Personnel expenses include the following: |
In thousands of soles |
2024 |
2023 |
2022 |
|||||||||
Remunerations |
||||||||||||
Legal bonuses |
||||||||||||
Health insurance for employees |
||||||||||||
Bonuses |
||||||||||||
Severance payments |
||||||||||||
Vacations |
||||||||||||
Employees’ profit sharing |
||||||||||||
Board of Directors’ remuneration |
||||||||||||
Equity-settled share-based payment expenses |
— | |||||||||||
Compensation to personnel |
||||||||||||
Training |
||||||||||||
Other benefits |
||||||||||||
| (b) | Services provided by third parties include the following: |
In thousands of soles |
2024 |
2023 |
2022 |
|||||||||
Sales commissions |
||||||||||||
Advisory and consulting fees |
||||||||||||
Leases |
||||||||||||
Credit card commissions |
||||||||||||
Service and repair |
||||||||||||
Custodial and cleaning services |
||||||||||||
Advertisement |
||||||||||||
Utilities |
||||||||||||
Hosting |
||||||||||||
Collection expenses |
||||||||||||
Travel and entertainment expenses |
||||||||||||
Others |
||||||||||||
| (c) | For the years ended December 31, 2024 and 2023, personnel expenses, services provided by third parties and other management charges include the amortization of the account “insurance acquisition cash flows” of S/ |
22. |
Other Income |
In thousands of soles |
2024 |
2023 |
2022 |
|||||||||
Income for parking (a) |
||||||||||||
Indemnification for claims |
||||||||||||
Investment property rentals |
||||||||||||
Increase in fair value of investment property |
||||||||||||
Receivable recoveries (b) |
||||||||||||
Tax recoveries |
— | — | ||||||||||
Other income for derecognition of other accounts payables to former shareholders (d) |
— | — | ||||||||||
Other income for reversal of contingent consideration |
— | — | ||||||||||
Gain on sale of property, furniture and equipment |
||||||||||||
Debt forgiveness and donations received |
— | — | ||||||||||
Others (c) |
||||||||||||
| (a) | Corresponds to the administration, parking and valet parking services provided by the clinics. Income for parking is recognized once the service has been rendered. |
| (b) | Mainly corresponds to recoveries of receivables that were expected as uncollectable at the acquisition date of Oncomedica S.A. |
| (c) | Mainly corresponds to income from food services (cafeteria), income from teaching services and other miscellaneous income of the Mexican Component. |
| (d) | This caption includes S/ |
In thousands of soles |
Note |
2024 |
2023 |
|||||||||
Balances as of January 1, |
||||||||||||
Interest expense |
||||||||||||
Payments |
( |
) | ( |
) | ||||||||
Reversal |
( |
) | — | |||||||||
Hospital y Clínica OCA’s purchase price adjustment (*) |
— | ( |
) | |||||||||
Transfer from Contingent consideration |
17(d) |
— | ||||||||||
Acquired through business combination |
— | |||||||||||
Exchange difference |
( |
) | ||||||||||
Balances as of December 31 |
||||||||||||
(*) |
In June 2023, the Group adjusted the purchase price of the acquisition of Hospital y Clínica OCA performed in October 2022 in accordance with the acquisition Share Purchase Agreement for S/ |
23. |
Other Expenses |
In thousands of soles |
Note |
2024 |
2023 |
2022 |
||||||||||||
Changes in contingent consideration |
24.d |
— | — | |||||||||||||
Derecognition of other assets |
— | — | ||||||||||||||
Loss on disposal of intangibles |
— | — | ||||||||||||||
24. |
Net Finance Costs |
In thousands of soles |
2024 |
2023 |
2022 |
|||||||||
Finance income |
||||||||||||
Interest income under the effective interest |
||||||||||||
Cash flow hedges settlement - Swaps |
— | — | ||||||||||
Interest on term deposits |
||||||||||||
Exchange difference (a) |
— | — | ||||||||||
Interest income on other investments |
— | |||||||||||
Others |
||||||||||||
In thousands of soles |
Note |
2024 |
2023 |
2022 |
||||||||||
Finance cost |
||||||||||||||
Financial liabilities measured at amortized cost – interest expense (c) |
||||||||||||||
Interest from leases liabilities |
||||||||||||||
Exchange difference (a) |
— | |||||||||||||
Cash flow hedges - reclassified from OCI for costs of hedging reserve |
||||||||||||||
Change in fair value of contingent consideration (d) |
||||||||||||||
Financial assets at FVTPL – net change in fair value: Derivate assets mandatorily measured at FVTPL |
||||||||||||||
Extinguishment of debt |
15.a |
— | ||||||||||||
Financial debt prepayment penalty |
15.a |
— | ||||||||||||
Unwind of derivative financial instruments measured at FVOCI |
— | — | ||||||||||||
Cash flow hedges settlement - Swaps |
— | — | ||||||||||||
Others (b) |
||||||||||||||
| (a) | In 2024, the net exchange difference includes an effect for S/ |
| (b) | For years 2024, 2023 and 2022, this includes mainly cost of factoring for S/ |
| (c) | For years 2024, 2023 and 2022, this includes S/ |
| (d) | The movement of contingent consideration is the following: |
In thousands of soles |
2024 |
2023 |
2022 |
|||||||||
Balances as of January 1, |
||||||||||||
Acquired through business combination |
— | — | ||||||||||
Reversal |
— | ( |
) | — | ||||||||
Change in fair value of contingent consideration |
||||||||||||
Payment of contingent consideration |
( |
) | ( |
) | ( |
) | ||||||
Transfer to Account payables to former shareholder, Note 17 (d) |
( |
) | — | — | ||||||||
Change in fair value of contingent consideration |
— | — | ||||||||||
Exchange difference |
( |
) | ( |
) | ||||||||
Balances as of December 31 |
— |
|||||||||||
25. |
Earnings per Share |
In thousands of soles |
2024 |
2023 |
2022 |
|||||||||
Net profit (loss) for the year attributable to owners of the Company |
( |
) | ( |
) | ||||||||
Number of shares |
||||||||||||
Weighted average number of ordinary shares at December 31 (Basic) |
||||||||||||
Weighted average number of ordinary shares at December 31 (Diluted) |
||||||||||||
Basic earnings per share |
( |
) |
( |
) | ||||||||
Diluted earnings per share |
( |
) |
( |
) | ||||||||
26. |
Operating Segments |
A. |
Basis for segmentation |
Reportable segments |
Operations | |
B. |
Information about reportable segments |
Reportable segments |
||||||||||||||||||||||||||||
In thousands of soles |
Oncosalud Peru |
Healthcare services in Peru |
Healthcare services in Colombia |
Healthcare services in Mexico |
Total reportable segments |
Holding and eliminations |
Total |
|||||||||||||||||||||
2024 |
||||||||||||||||||||||||||||
External revenues |
— | |||||||||||||||||||||||||||
Inter-segment revenue (i) |
— | — | ( |
) | — | |||||||||||||||||||||||
Segment revenue |
( |
) |
||||||||||||||||||||||||||
External cost of service |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | — | ( |
) | |||||||||||||||
Inter-segment cost of service (i) |
( |
) | ( |
) | — | — | ( |
) | — | |||||||||||||||||||
Segment cost of service |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||
Gross profit |
( |
) |
||||||||||||||||||||||||||
External selling expenses |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||
Segment selling expenses |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||
External administrative expenses |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | — | ( |
) | |||||||||||||||
Inter-segment administrative expenses |
( |
) | ( |
) | — | — | ( |
) | — | |||||||||||||||||||
Corporate expenses |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||
Segment administrative expenses |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||
Impairment losses on trade receivables |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||
Other expenses |
— |
— |
— |
— |
— |
( |
) |
( |
) | |||||||||||||||||||
Other income |
( |
) | ||||||||||||||||||||||||||
Inter-segment other income |
— | — | ( |
) | ||||||||||||||||||||||||
Other income |
( |
) |
||||||||||||||||||||||||||
Segment operating profit (loss) |
( |
) |
||||||||||||||||||||||||||
Share of profit of equity accounted investees, net of taxes |
— | — | — | |||||||||||||||||||||||||
Exchange difference, net |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||
Interest expense, net |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||
Segment profit (loss) before tax |
( |
) |
( |
) |
||||||||||||||||||||||||
Other disclosures |
||||||||||||||||||||||||||||
Depreciation and amortization |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||
Capital expenditure |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||
Segment assets |
( |
) |
||||||||||||||||||||||||||
Segment liabilities |
||||||||||||||||||||||||||||
Reportable segments |
||||||||||||||||||||||||||||
In thousands of soles |
Oncosalud Peru |
Healthcare services in Peru |
Healthcare services in Colombia |
Healthcare services in Mexico |
Total reportable segments |
Holding and eliminations |
Total |
|||||||||||||||||||||
2023 |
||||||||||||||||||||||||||||
External revenues |
— | |||||||||||||||||||||||||||
Inter-segment revenue (i) |
— | — | ( |
) | — | |||||||||||||||||||||||
Segment revenue |
( |
) |
||||||||||||||||||||||||||
External cost of service |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | — | ( |
) | |||||||||||||||
Inter-segment cost of service (i) |
( |
) | ( |
) | — | — | ( |
) | — | |||||||||||||||||||
Segment cost of service |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||
Gross profit |
( |
) |
||||||||||||||||||||||||||
External selling expenses |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||
Segment selling expenses |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||
External administrative expenses |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | — | ( |
) | |||||||||||||||
Inter-segment administrative expenses |
( |
) | ( |
) | — | — | ( |
) | — | |||||||||||||||||||
Corporate expenses |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||
Segment administrative expenses |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||
Impairment losses on trade receivables |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||
Other expenses |
( |
) |
— | ( |
) |
— | ( |
) |
( |
) | ||||||||||||||||||
Other income |
( |
) | ||||||||||||||||||||||||||
Inter-segment other income |
— | — | ( |
) | — | |||||||||||||||||||||||
Other income |
( |
) |
||||||||||||||||||||||||||
Segment operating profit (loss) |
( |
) |
||||||||||||||||||||||||||
Share of profit of equity accounted investees, net of taxes |
— | — | — | |||||||||||||||||||||||||
Exchange difference, net |
( |
) | ( |
) | ( |
) | ||||||||||||||||||||||
Interest expense, net |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||
Segment profit (loss) before tax |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||
Other disclosures |
||||||||||||||||||||||||||||
Depreciation and amortization |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||
Capital expenditure |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||
Segment assets |
( |
) |
||||||||||||||||||||||||||
Segment liabilities |
||||||||||||||||||||||||||||
Reportable segments |
||||||||||||||||||||||||||||
In thousands of soles |
Oncosalud Peru |
Healthcare services in Peru |
Healthcare services in Colombia |
Healthcare services in Mexico |
Total reportable segments |
Holding and eliminations |
Total |
|||||||||||||||||||||
2022 |
||||||||||||||||||||||||||||
External revenues |
— | |||||||||||||||||||||||||||
Inter-segment revenue (i) |
— | — | ( |
) | — | |||||||||||||||||||||||
Segment revenue |
( |
) |
||||||||||||||||||||||||||
External cost of service |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | — | ( |
) | |||||||||||||||
Inter-segment cost of service (i) |
( |
) | ( |
) | — | — | ( |
) | — | |||||||||||||||||||
Segment cost of service |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||
Gross profit |
( |
) |
||||||||||||||||||||||||||
External selling expenses |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||
Segment selling expenses |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||
External administrative expenses |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | — | ( |
) | |||||||||||||||
Inter-segment administrative expenses |
( |
) | ( |
) | — | — | ( |
) | — | |||||||||||||||||||
Corporate expenses |
( |
) | ( |
) | ( |
) | — | ( |
) | ( |
) | |||||||||||||||||
Segment administrative expenses |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||
Impairment losses on trade receivables |
( |
) |
( |
) |
— |
|||||||||||||||||||||||
Other expenses |
— | — | — | — | — | ( |
) | ( |
) | |||||||||||||||||||
Other income |
( |
) | ||||||||||||||||||||||||||
Inter-segment other income |
— | — | ( |
) | — | |||||||||||||||||||||||
Other income |
( |
) |
||||||||||||||||||||||||||
Segment operating profit (loss) |
( |
) |
||||||||||||||||||||||||||
Share of profit of equity accounted investees, net of taxes |
— | — | — | |||||||||||||||||||||||||
Exchange difference, net |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||
Interest expense, net |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||
Segment profit (loss) before tax |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||
Other disclosures |
||||||||||||||||||||||||||||
Depreciation and amortization |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||
Capital expenditure |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||
Segment assets |
( |
) |
||||||||||||||||||||||||||
Segment liabilities |
||||||||||||||||||||||||||||
| (i) | Inter-segment cost of service (claims expense) from the Oncosalud Peru segment and intersegment revenue from our Healthcare Services in Peru segment are presented on a gross basis by adding the corresponding profit margin markup by our Healthcare Services in Peru segment and vice versa. Likewise, our Oncosalud Peru segment consolidates Oncocenter Perú S.A.C., a subsidiary providing healthcare services related to the exclusive treatment of cancer. In the separate financial statements of Oncocenter Perú S.A.C., the revenue mainly consists of the insurance claims expense recorded as cost of sales in the separate financial statements of Oncosalud S.A.C., our insurance subsidiary that is also consolidated in Oncosalud Peru segment. In the segment consolidation process, the related revenues from such healthcare services are eliminated with the corresponding claims expense of our insurance subsidiary Oncosalud S.A.C., while the external cost (third parties) of services incurred by Oncocenter Perú S.A.C. remains. |
C. |
Geographic information |
In thousands of soles |
2024 |
2023 |
2022 |
|||||||||
Revenue |
||||||||||||
Peru |
||||||||||||
Colombia |
||||||||||||
México |
||||||||||||
Non-current assets (*) |
||||||||||||
Peru |
||||||||||||
Colombia |
||||||||||||
México |
||||||||||||
(*) |
Non-current assets exclude deferred tax assets and derivatives. |
D. |
Major customer |
27. |
Tax Matters |
| A. | Income tax is determined on a separate basis; it is not consolidated. According to Peruvian, Colombian, Mexican and Luxembourg current legal legislations, the income tax is paid based on the statutory financial statements and tax losses, additions, and deductions established. |
| B. | The Group is subject to Peruvian, Colombian, Mexican and Luxembourg Tax Regimes as of December 31, 2024, 2023 and 2022. |
| C. | The Group computed its taxable income for the years ended December 31, 2024, 2023 and 2022, and determined current income tax for S/ |
In thousands of soles |
Note |
2024 |
2023 |
2022 |
||||||||||||
Current |
||||||||||||||||
Deferred |
14 |
( |
) | ( |
) | ( |
) | |||||||||
Income tax |
||||||||||||||||
In thousands of soles |
2024 |
2023 |
2022 |
|||||||||||||||||||||
Profit (loss) before income tax |
% |
( |
) |
% |
( |
) |
% | |||||||||||||||||
Tax using the Company’s domestic tax rate (a) |
% | ( |
) | % | ( |
) | % | |||||||||||||||||
Effect of tax rates of a subsidiary abroad |
% | ( |
) | % | ( |
) | % | |||||||||||||||||
Non deductible expenses |
( |
%) | ( |
%) | ( |
%) | ||||||||||||||||||
Tax losses for which deferred tax asset was not recognized |
% | ( |
%) | ( |
%) | |||||||||||||||||||
Derecognition of previously recognized deductible temporary differences |
— | — | ( |
%) | ( |
%) | ||||||||||||||||||
Recognition of previously unrecognized tax losses |
( |
) | ( |
%) | — | — | — | — | ||||||||||||||||
Changes in tax rate (Colombia) |
% | ( |
%) | — | — | |||||||||||||||||||
Annual adjustment for inflation |
% | ( |
%) | ( |
%) | |||||||||||||||||||
Changes in estimates related to prior years |
% | ( |
%) | ( |
) | % | ||||||||||||||||||
Income tax |
% |
( |
%) |
( |
%) | |||||||||||||||||||
| D. | The Group has recognized a deferred income tax asset related to the tax-loss carryforward of those subsidiaries where it is more likely than not that the tax-loss carryforward can be used to compensate future taxable net income. |
In thousands of soles |
2024 |
Expiration date |
2023 |
Expiration date |
2022 |
Expiration date |
||||||||||||||||||
Expire |
||||||||||||||||||||||||
Never expire |
— | — | — | |||||||||||||||||||||
Income tax |
||||||||||||||||||||||||
| (i) | The tax loss may be offset with future income until it is extinguished, applying said loss up to |
| (ii) | The tax loss may be used until four years after it has been generated. |
| (i) | Tax losses established until 2016 do not expire, while tax losses generated as of 2017 can be carried forward for 11 years. |
| (ii) | Tax losses generated can be carried forward for 10 years. |
| (iii) | Tax losses generated can be carried forward for 17 years. |
| E. | Deferred tax assets for certain subsidiaries have not been recognized in respect of the following item, because it is not probable that future taxable profit will be available against which the Group can use the benefits therefrom. |
2024 |
2023 |
2022 |
||||||||||||||||||||||
In thousands of soles |
Gross amount |
Tax effect |
Gross amount |
Tax effect |
Gross amount |
Tax effect |
||||||||||||||||||
Tax losses |
||||||||||||||||||||||||
| F. | The Group is subject to the Temporary Tax on Net Assets (ITAN, from its Spanish acronym) in Peru. The taxable base is the prior period adjusted net asset value less depreciation and amortization, admitted by the Income Tax Law. |
| G. | For the purpose of determining the Income Tax, the transfer prices of transactions with related parties and with companies domiciled in countries or territories that are noncooperating or low or zero tax countries or territories, or with entities or permanent establishments whose income, revenues or gains from said contracts are subject to a preferential tax regime, must be supported by documented information on the valuation methods used and the criteria considered for their determination. On the basis of the analysis of the operations of the Group’s subsidiaries, Management and its internal legal advisors believe that, as a consequence of the application of these standards, contingencies of the subsidiaries domiciled in Peru, Colombia, Mexico and Luxembourg will not arise as of December 31, 2024, 2023 and 2022. |
| H. | The Peruvian and Colombian tax authorities are entitled to audit and, if applicable, to correct the income tax calculated by the Group’s entities within the four years following the year of the tax return filing. The Group’s income tax returns for the years 2018 through 2022 are open for review by the Peruvian and Colombian tax authority. The Mexican and Luxembourg tax authorities are entitled to audit and, if applicable, to correct the income tax calculated by the Group’s entities within the five years following the year of the tax return filing. The income tax returns for the years 2017 through 2022 are open for review by the Mexican and Luxembourg tax authorities. |
| I. | The Group’s sales tax returns are open for review by the Peruvian, Colombian, Mexican and Luxembourg tax authorities, in the same years indicated in the previous paragraph. |
| J. | For Peruvian, Colombian, Mexican and Luxembourg companies, the value added tax (VAT) is |
| K. | The Group believes that its accrual for tax liabilities is adequate for all open tax years based on its assessment of many factors, including interpretations of tax law and prior experience. |
| L. | In Luxembourg, the Parliament adopted the bill of law 8292 implementing Council Directive (EU) 2022/2523 dated December 14, 2022 on ensuring a global minimum level of taxation for multinational enterprise groups and large-scale domestic groups in the EU, commonly known as Pillar Two, on December 20, 2023 and the law was published in the official gazette on December 22, 2023, therefore Lux Pillar Two is only effective as of January 1, 2024 and it has not been enacted in Peru, Colombia nor Mexico. |
| • | As of December 31, 2024, the consolidated Group’s revenue did not exceed EUR |
| • | Management has no expectation to obtain an effective tax rate of |
28. |
Group Structure |
In thousands of soles |
Country of incorporation and operations |
Percentage of common shares held by the Group (%) |
Percentage of common shares held by the non-controlling interest |
|||||||||||||||||||||||||
2024 |
2023 |
2022 |
2024 |
2023 |
2022 |
|||||||||||||||||||||||
Operating companies |
||||||||||||||||||||||||||||
Pre-operating companies |
||||||||||||||||||||||||||||
Non-operating companies |
||||||||||||||||||||||||||||
Holdings companies |
||||||||||||||||||||||||||||
Other subsidiaries |
||||||||||||||||||||||||||||
| (a) | Mainly dedicated to providing oncologic healthcare services. |
| (b) | Mainly dedicated to providing services through health centers (inpatients and outpatients). |
| (c) | Holdings of the Group. Auna Colombia is a holding located in the Republic of Colombia and Grupo Salud Auna México, S.A. de C.V. is a holding located in the Republic of Mexico. |
| (d) | Mainly dedicated to providing the Group with internal administrative, commercial, real estate and management services. |
29. |
Financial Risk and Insurance Management |
A. |
Insurance risk |
In thousands of soles |
Frequency |
Frequency |
Average cost per patient |
Average cost per patient |
Combined |
Combined |
||||||||||||||||||||||
2024 |
||||||||||||||||||||||||||||
Change % |
+5 | % | +10 | % | +5 | % | +10 | % | +5 | % | +10 | % | ||||||||||||||||
Cost of segment Oncosalud Peru |
||||||||||||||||||||||||||||
Frequency |
% | % | % | % | % | % | % | |||||||||||||||||||||
Average cost per patient |
||||||||||||||||||||||||||||
# of plan members |
||||||||||||||||||||||||||||
In thousands of soles |
Frequency |
Frequency |
Average cost per patient |
Average cost per patient |
Combined |
Combined |
||||||||||||||||||||||
2023 |
||||||||||||||||||||||||||||
Change % |
+5 | % | +10 | % | +5 | % | +10 | % | +5 | % | +10 | % | ||||||||||||||||
Cost of segment Oncosalud Peru |
||||||||||||||||||||||||||||
Frequency |
% | % | % | % | % | % | % | |||||||||||||||||||||
Average cost per patient |
||||||||||||||||||||||||||||
# of plan members |
||||||||||||||||||||||||||||
In thousands of soles |
Frequency |
Frequency |
Average cost per patient |
Average cost per patient |
Combined |
Combined |
||||||||||||||||||||||
2022 |
||||||||||||||||||||||||||||
Change % |
+ 5 | % | + 10 | % | + 5 | % | + 10 | % | + 5 | % | + 10 | % | ||||||||||||||||
Cost of segment Oncosalud Peru |
||||||||||||||||||||||||||||
Frequency |
% | % | % | % | % | % | % | |||||||||||||||||||||
Average cost per patient |
||||||||||||||||||||||||||||
# of plan members |
||||||||||||||||||||||||||||
In thousands of soles |
Fluctuations in variables (%) |
2024 |
2023 |
2022 |
||||||||||||
Profit for the year |
Profit for the year |
Profit for the year |
||||||||||||||
Frequency |
( |
) | ( |
) | ( |
) | ||||||||||
Frequency |
( |
) | ( |
) | ( |
) | ||||||||||
Average cost per patient |
( |
) | ( |
) | ( |
) | ||||||||||
Average cost per patient |
( |
) | ( |
) | ( |
) | ||||||||||
Combined |
( |
) | ( |
) | ( |
) | ||||||||||
Combined |
( |
) | ( |
) | ( |
) | ||||||||||
B. |
Market risk |
i. |
Exchange risk |
In thousands of |
2024 |
2023 |
2022 |
|||||||||||||||||||||||||||||
US$ |
COP |
MXN |
US$ |
COP |
MXN |
US$ |
COP |
|||||||||||||||||||||||||
Assets |
||||||||||||||||||||||||||||||||
Cash and cash equivalents |
||||||||||||||||||||||||||||||||
Trade accounts receivable |
||||||||||||||||||||||||||||||||
Other assets |
||||||||||||||||||||||||||||||||
Derivative financial instruments |
— | — | — | — | ||||||||||||||||||||||||||||
Liabilities |
||||||||||||||||||||||||||||||||
Loans and borrowings |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||
Lease liabilities |
( |
) | ( |
) | — | ( |
) | ( |
) | — | ( |
) | ( |
) | ||||||||||||||||||
Trade accounts payable |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||
Other accounts payable |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||
Derivative financial instruments |
( |
) | — | ( |
) | — | — | — | ( |
) | — | |||||||||||||||||||||
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | |||||||||||||||||
Liability position, net |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||
In soles |
2024 |
2023 |
2022 |
|||||||||
US$ 1 - Exchange rate - Buy (assets) |
||||||||||||
US$ 1 - Exchange rate - Sale (liabilities) |
||||||||||||
COP 1 - Exchange rate |
||||||||||||
MXN 1- Exchange rate |
||||||||||||
In thousands of soles |
Fluctuations in exchange rates (%) |
2024 |
2023 |
2022 |
||||||||||||||||||||||||
Profit or loss for the fiscal year |
Other comprehensive income |
Profit or loss for the fiscal year |
Other comprehensive income |
Profit or loss for the fiscal year |
Other comprehensive income |
|||||||||||||||||||||||
Weakening |
( |
) | ( |
) | ( |
) | ||||||||||||||||||||||
Weakening |
( |
) | ( |
) | ( |
) | ||||||||||||||||||||||
Strengthening |
( |
) | ( |
) | ( |
) | ||||||||||||||||||||||
Strengthening |
( |
) | ( |
) | ( |
) | ||||||||||||||||||||||
ii. |
Interest rate risk |
In thousands of Soles |
Fluctuations in interest rates (%) |
2024 |
||||||
Profit or (loss) for the fiscal year |
||||||||
Decrease |
||||||||
Decrease |
||||||||
Increase |
( |
) | ||||||
Increase |
( |
) | ||||||
C. |
Credit risk |
In thousands of soles |
2024 |
2023 |
2022 |
|||||||||
Peru |
||||||||||||
Colombia |
||||||||||||
México |
||||||||||||
D. |
Liquidity risk |
| • | Auna S.A. can finance its current assets (accounts receivable, inventories and others) with current liabilities (accounts payable, deferred revenue and others). |
| • | Auna S.A. analyses the maturity of its debts to identify any refinancing required to maintain an appropriate debt structure. |
| • | Not considering growth capex (new hospitals, acquisitions, etc.), Auna has enough cash flow from operations to finance its maintenance capex, current debt service (interest and principal), dividends and a portion of growth capex. |
| • | Growth capex is financed mainly by long-term debt and cash flow from operations. In some cases, by capital contribution (for example: acquisition of PMLA and Hospital y Clínica OCA). |
| • | In addition, Auna has revolving credit lines of S/ |
| • | These credit lines are renewed every year. The interest rate applicable for the lines in Peru is a fixed rate that is agreed upon with the bank before the reception of the cash in Auna accounts and depends on the credit terms (up to |
In thousands of soles |
Carrying amount |
Contractual cash flows |
Less than 1 year |
From 1 to 2 years |
From 3 to 5 years |
More than 5 years |
||||||||||||||||||
2024 |
||||||||||||||||||||||||
Trade accounts payable |
— | — | ||||||||||||||||||||||
Other accounts payable (*) |
— | |||||||||||||||||||||||
Loans and borrowings (**) |
||||||||||||||||||||||||
Lease liabilities (**) |
||||||||||||||||||||||||
Derivative financial instruments |
— | |||||||||||||||||||||||
2023 |
||||||||||||||||||||||||
Trade accounts payable |
— | — | ||||||||||||||||||||||
Other accounts payable (*) |
— | |||||||||||||||||||||||
Loans and borrowings (**) |
||||||||||||||||||||||||
Lease liabilities (**) |
||||||||||||||||||||||||
2022 |
||||||||||||||||||||||||
Trade accounts payable |
— | — | ||||||||||||||||||||||
Other accounts payable (*) |
— | |||||||||||||||||||||||
Loans and borrowings (**) |
||||||||||||||||||||||||
Lease liabilities (**) |
||||||||||||||||||||||||
Derivative financial instruments |
— | — | — | |||||||||||||||||||||
(*) |
They do not include taxes payable, remunerations and other benefits payable. |
(**) |
They include contractual interest. |
E. |
Capital risk management |
In thousands of soles |
2024 |
2023 |
2022 |
|||||||||
Total loans and borrowings |
||||||||||||
Less: Cash and cash equivalents |
( |
) | ( |
) | ( |
) | ||||||
Net debt (A) |
||||||||||||
Plus: Total equity |
||||||||||||
Total adjusted equity (B) |
||||||||||||
Leverage ratio (A)/(B) |
||||||||||||
F. |
Accounting classification and fair value |
Carrying amount |
Fair value |
|||||||||||||||||||||||||||||||||||
In thousands of soles |
FVOCI – debt instruments |
Fair value hedging instruments |
Financial assets at amortized cost |
Other financial liabilities |
Total |
Level 1 |
Level 2 |
Level 3 |
Total |
|||||||||||||||||||||||||||
As of December 31, 2024 |
||||||||||||||||||||||||||||||||||||
Financial assets measured at fair value |
||||||||||||||||||||||||||||||||||||
Other investments |
— | — | — | — | — | |||||||||||||||||||||||||||||||
Derivative financial instruments |
— | — | — | — | — | |||||||||||||||||||||||||||||||
— |
— |
— |
||||||||||||||||||||||||||||||||||
Financial assets not measured at fair value |
||||||||||||||||||||||||||||||||||||
Cash and cash equivalents |
— | — | — | — | — | — | — | |||||||||||||||||||||||||||||
Trade accounts receivable |
— | — | — | — | — | — | — | |||||||||||||||||||||||||||||
Other assets (*) |
— | — | — | — | — | — | — | |||||||||||||||||||||||||||||
— |
— |
— |
— |
— |
— |
— |
||||||||||||||||||||||||||||||
Financial liabilities measured at fair value |
||||||||||||||||||||||||||||||||||||
Derivative financial instruments |
— | — | — | — | — | |||||||||||||||||||||||||||||||
— |
— |
— |
— |
— |
||||||||||||||||||||||||||||||||
Financial liabilities not measured at fair value |
||||||||||||||||||||||||||||||||||||
Loans and borrowings |
— | — | — | — | — | |||||||||||||||||||||||||||||||
Lease liabilities |
— | — | — | — | — | — | — | |||||||||||||||||||||||||||||
Trade accounts payable |
— | — | — | — | — | — | — | |||||||||||||||||||||||||||||
Other accounts payable (**) |
— | — | — | — | — | — | — | |||||||||||||||||||||||||||||
— |
— |
— |
— |
— |
||||||||||||||||||||||||||||||||
(*) |
They do not include taxes receivable and prepayments. |
(**) |
They do not include taxes payable, prepayments and labor liabilities |
Carrying amount |
Fair value |
|||||||||||||||||||||||||||||||||||
In thousands of soles |
FVOCI – debt instruments |
Fair value hedging instruments |
Financial assets at amortized cost |
Other financial liabilities |
Total |
Level 1 |
Level 2 |
Level 3 |
Total |
|||||||||||||||||||||||||||
As of December 31, 2023 |
||||||||||||||||||||||||||||||||||||
Financial assets measured at fair value |
||||||||||||||||||||||||||||||||||||
Other investments |
— | — | — | — | — | |||||||||||||||||||||||||||||||
Derivative financial instruments |
— | — | — | — | — | |||||||||||||||||||||||||||||||
— |
— |
— |
||||||||||||||||||||||||||||||||||
Financial assets not measured at fair value |
||||||||||||||||||||||||||||||||||||
Cash and cash equivalents |
— | — | — | — | — | — | — | |||||||||||||||||||||||||||||
Trade accounts receivable |
— | — | — | — | — | — | — | |||||||||||||||||||||||||||||
Other assets (*) |
— | — | — | — | — | — | — | |||||||||||||||||||||||||||||
— |
— |
— |
— |
— |
— |
— |
||||||||||||||||||||||||||||||
Financial liabilities measured at fair value |
||||||||||||||||||||||||||||||||||||
Contingent consideration |
— | — | — | — | — | |||||||||||||||||||||||||||||||
Put liability |
— | — | — | — | — | |||||||||||||||||||||||||||||||
— |
— |
— |
— |
— |
||||||||||||||||||||||||||||||||
Financial liabilities not measured at fair value |
||||||||||||||||||||||||||||||||||||
Loans and borrowings |
— | — | — | — | — | |||||||||||||||||||||||||||||||
Lease liabilities |
— | — | — | — | — | — | — | |||||||||||||||||||||||||||||
Trade accounts payable |
— | — | — | — | — | — | — | |||||||||||||||||||||||||||||
Other accounts payable (**) |
— | — | — | — | — | — | ||||||||||||||||||||||||||||||
— |
— |
— |
— |
— |
||||||||||||||||||||||||||||||||
(*) |
They do not include taxes receivable and prepayments. |
(**) |
They do not include taxes payable, prepayments and labor liabilities |
Carrying amount |
Fair value |
|||||||||||||||||||||||||||
In thousands of soles |
Fair value hedging instruments |
Financial assets at amortized cost |
Other financial liabilities |
Total |
Level 2 |
Level 3 |
Total |
|||||||||||||||||||||
As of December 31, 2022 |
||||||||||||||||||||||||||||
Financial assets measured at fair value |
||||||||||||||||||||||||||||
Derivative financial instruments |
— | — | — | |||||||||||||||||||||||||
— |
— |
— |
||||||||||||||||||||||||||
Financial assets not measured at fair value |
||||||||||||||||||||||||||||
Cash and cash equivalents |
— | — | — | — | — | |||||||||||||||||||||||
Trade accounts receivable |
— | — | — | — | — | |||||||||||||||||||||||
Other assets (*) |
— | — | — | — | — | |||||||||||||||||||||||
— |
— |
— |
— |
— |
||||||||||||||||||||||||
Financial liabilities measured at fair value |
||||||||||||||||||||||||||||
Derivative financial instruments |
— | — | — | |||||||||||||||||||||||||
Contingent consideration |
— | — | — | |||||||||||||||||||||||||
Put liability |
— | — | — | |||||||||||||||||||||||||
— |
||||||||||||||||||||||||||||
Financial liabilities not measured at fair value |
||||||||||||||||||||||||||||
Loans and borrowings |
— | — | — | |||||||||||||||||||||||||
Lease liabilities |
— | — | — | — | — | |||||||||||||||||||||||
Trade accounts payable |
— | — | — | — | — | |||||||||||||||||||||||
Other accounts payable (**) |
— | — | — | — | — | |||||||||||||||||||||||
— |
— |
— |
||||||||||||||||||||||||||
(*) |
They do not include taxes receivable and prepayments. |
(**) |
They do not include taxes payable, prepayments and labor liabilities |
G. |
Measurement of fair values |
i. |
Valuation techniques and significant unobservable inputs |
Type |
Valuation technique |
Significant unobservable inputs |
Inter-relationship between significant unobservable inputs and fair value | |||
| Put liability (note 17) | Discounted cash flows: The valuation model considers the present value of the expected future payments, discounted using a risk-adjusted discount rate. | • Expected cash flows (December 31, 2023: COP Risk-adjusted discount rate ( |
The estimated fair value would increase (decrease) if: • the expected cash flows were higher (lower); or • the risk-adjusted discount rate were lower (higher). | |||
Contingent consideration (note 17) |
Discounted cash flows: The valuation model considers the present value of the expected future payments, discounted using a risk-adjusted discount rate. | • Expected cash flows (December 31, 2023: COP • Risk-adjusted discount rate (December 31, 2023: |
The estimated fair value would increase (decrease) if: • the expected cash flows were higher (lower); or • the risk-adjusted discount rate were lower (higher). | |||
| Derivatives financial instruments (note 8) | For the Options: Garman–Kohlhagen: The fair value is determined using this model that treats foreign currencies as if they are equity securities that provide a known dividend yield, which uses the following inputs: Spot rate at the valuation date, strike price, implicit volatility, and risk-free rate in both currencies. For long-forward/swap: Interest rate parity: Consists of estimating the present value of the future profit (loss) generated by the forward/swap contract. The gain or loss is calculated as the difference between the forward exchange rate estimated according to the market and the strike. |
Not applicable | Not applicable | |||
ii. |
Sensitivity analysis |
December 31, 2023 |
||||||||
In thousands of soles |
Increase |
Decrease |
||||||
Contingent consideration |
Profit or loss |
|||||||
Expected cash flows ( |
( |
) | ||||||
Risk-adjusted discount rate ( |
( |
) | ||||||
Put liability |
Other comprehensive loss |
|||||||
Expected cash flows ( |
( |
) | ||||||
Risk-adjusted discount rate ( |
— | — | ||||||
December 31, 2022 |
||||||||
In thousands of soles |
Increase |
Decrease |
||||||
Contingent consideration |
Profit or loss |
|||||||
Expected cash flows ( |
( |
) | ||||||
Risk-adjusted discount rate ( |
( |
) | ||||||
Put liability |
Other comprehensive loss |
|||||||
Expected cash flows ( |
( |
) | ||||||
Risk-adjusted discount rate ( |
( |
) | ||||||
30. |
Commitments, Guarantees and Contingencies |
A. |
Commitments |
B. |
Guarantees |
| • | Guarantee letters in financial institutions for S/ |
| • | Guarantee to cover a financial loan for a total of S/ |
| • | The Group maintains properties in mortgage in favor of Scotiabank Perú S.A.A. for S/ |
| • | Colombian subsidiaries maintain guarantee trust for S/ |
| • | The |
| • | The Company and its subsidiaries engage as issuer and guarantors, respectively, in the issuance and placement of Senior Notes at a rate of |
| • | The Company and its subsidiaries engage as co-debtor and guarantors, respectively, in the Credit Agreement dated December 10,2023 for up to US$ |
C. |
Contingencies liabilities |
31. |
Related Parties |
Transaction value |
Outstanding balances |
|||||||||||||||||||||||
In thousands of soles |
2024 |
2023 |
2022 |
2024 |
2023 |
2022 |
||||||||||||||||||
Sales of oncologic healthcare services |
||||||||||||||||||||||||
Joint ventures |
||||||||||||||||||||||||
Associates |
— | — | — | — | — | — | ||||||||||||||||||
Others |
||||||||||||||||||||||||
Cost of sales of oncologic healthcare services |
||||||||||||||||||||||||
Joint ventures |
||||||||||||||||||||||||
Associates |
||||||||||||||||||||||||
Others |
||||||||||||||||||||||||
Administrative expenses |
||||||||||||||||||||||||
Services provided by related parties (v) |
||||||||||||||||||||||||
Other management charges |
||||||||||||||||||||||||
Selling expenses |
||||||||||||||||||||||||
Services provided by related parties (vi) |
||||||||||||||||||||||||
Finance income |
||||||||||||||||||||||||
Loans and related interest from related parties |
— | — | — | — | ||||||||||||||||||||
— |
— |
— |
— |
|||||||||||||||||||||
| (i) | Compensation to key personnel |
| (ii) | Advances and loans granted to the Members of the Management and Supervisory Bodies |
| (iii) | Compensation to directors |
| (iv) | Medical services |
| (v) | Management expenses |
| (vi) | Selling expenses |
32. |
Insurance Contract Liabilities |
2024 |
2023 |
|||||||||||||||||||||||||||||||
Liabilities for incurred claims |
Liabilities for incurred claims |
|||||||||||||||||||||||||||||||
In thousands of soles |
Liabilities for remaining coverage |
Estimates of present value of future cash flows |
Risk adjustment for non-financial risk |
Total |
Liabilities for remaining coverage |
Estimates of present value of future cash flows |
Risk adjustment for non-financial risk |
Total |
||||||||||||||||||||||||
Balances as of January 1 |
||||||||||||||||||||||||||||||||
Changes in the statement of profit or loss and OCI |
— | — | — | — | — | — | — | — | ||||||||||||||||||||||||
Insurance revenue |
( |
) |
— |
— |
( |
) |
( |
) |
— |
— |
( |
) | ||||||||||||||||||||
Insurance service expenses |
||||||||||||||||||||||||||||||||
Incurred claims and other insurance service expenses |
— | — | — | — | ||||||||||||||||||||||||||||
Amortization of insurance acquisition cash flows |
— | — | — | — | ||||||||||||||||||||||||||||
Adjustments to liabilities for incurred claims |
— | — | ( |
) | ( |
) | — | — | ||||||||||||||||||||||||
Total insurance service expenses |
( |
) |
||||||||||||||||||||||||||||||
Total insurance service result |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||||
Effect of movements in exchange rates |
( |
) | ( |
) | ( |
) |
( |
) |
— | |||||||||||||||||||||||
Total changes in the statement of profit or loss and OCI |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||||
Cash flows |
||||||||||||||||||||||||||||||||
Premiums received |
— | — | — | — | ||||||||||||||||||||||||||||
Claims and other insurance service expenses paid |
— | ( |
) | — | ( |
) | — | ( |
) | — | ( |
) | ||||||||||||||||||||
Insurance acquisition cash flows |
( |
) | — | — | ( |
) | ( |
) | — | — | ( |
) | ||||||||||||||||||||
Total cash flows |
( |
) |
— |
( |
) |
— |
||||||||||||||||||||||||||
Acquired through business combinations |
— | — | — | — | ( |
) | — | |||||||||||||||||||||||||
Closing assets |
— |
— |
— |
— |
— |
— |
— |
— |
||||||||||||||||||||||||
Closing liabilities |
||||||||||||||||||||||||||||||||
Cost of sales and services (i) |
||||||||||||
| In thousands of soles |
2024 |
2023 |
2022 |
|||||||||
| Medicines |
||||||||||||
| Room service for inpatients |
||||||||||||
| Medical consultation fees |
||||||||||||
| Auxiliary services and clinical laboratory |
||||||||||||
| Surgery fees |
||||||||||||
| Insurance contracts |
||||||||||||
| |
|
|
|
|
|
|||||||
| |
|
|
|
|
|
|||||||
| (i) | These expenses are included in the cost of sales and services in our consolidated statement of profit or loss and other comprehensive income after deducting the margin markup. For the years ended December 31, 2024, 2023 and 2022, the margin applied was calculated using the same basis as what we charge third parties for these services, and the overall average margin applied in each period was |
33. |
Share-Based Payments |
A. |
Description of share-based payment arrangements |
i. |
Restricted shares plan |
| Grand date/ Directors entitled |
Number of shares in thousands |
Vesting conditions |
(In thousands of soles) |
|||||||||||
2024 |
2023 |
|||||||||||||
| Award 2024 - Grant to Directors on |
— | |||||||||||||
| Award 2023 - Grant to Directors on |
— | |||||||||||||
ii. |
Option and restricted stock unit plans |
| Incentive plans / Vesting Commencement Date |
Number of options / shares in thousands |
Vesting conditions |
Contractual life of options / shares |
(In thousands of soles) 2024 |
||||||||||
| Performance-Based Option Agreement on |
3 years’ service from grant date |
|||||||||||||
| Long-Term Incentive Management on |
4 years’ service from grant date |
|||||||||||||
| Restricted Stock Unit on |
3 years’ service from grant date |
|||||||||||||
B. |
Measurement of grant date fair values |
| Incentive plans |
Year |
Methodology of fair value |
Grace period |
Number of options / shares in thousands |
Annual volatility |
Risk- free rate |
Weighted average of fair value of options / shares (in soles) |
Vesting status | ||||||||||||||||||||
| Performance-Based Option Agreement |
2024 | Binomial | |
21/03/2024 to 21/03/2027 |
|
% | % | Partially vested | ||||||||||||||||||||
| Long-Term Incentive Management |
2024 | Black Scholes | |
21/03/2024 to 21/03/2028 |
|
% | % | Partially vested | ||||||||||||||||||||
| Restricted Stock Units |
2024 | Market value | |
21/03/2024 to 21/03/2027 |
|
— | — | Partially vested | ||||||||||||||||||||
34. |
Auditor Fees |
Year ended December 31, |
||||||||||||
| In thousands of soles |
2024 |
2023 |
2022 |
|||||||||
| Audit services fees (i) |
||||||||||||
| Tax services fees |
— | |||||||||||
| Other non-audit fees |
||||||||||||
| |
|
|
|
|
|
|||||||
| Total |
||||||||||||
| |
|
|
|
|
|
|||||||
| (i) | As of December 31, 2023 Audit services fees include S/ |
35. |
Subsequent Events |